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ABBREVIATIONS 
 
Ab:    Antibody 
Ag:    Antigen 
APC:    Antigen-presenting cell 
BM  Bone marrow 
CNS:  Central nervous system 
CTL:  Cytotoxic T lymphocyte 
DC:    Dendritic cell 
EAE:    Experimental autoimmune encephalomyelitis 
FDC:    Follicular dendritic cell 
GC:    Germinal center 
Ig:    Immunoglobulin 
IFNγ:   Interferon gamma 
IL:    Interleukin 
LPS:  Lipopolysaccharide 
LTα:    Lymphotoxin alpha 
LTβR:   Lymphotoxin beta receptor 
MBP:    Myelin basic protein 
MHCI:   Major histocompatibility complex class I 
MHCII:  Major histocompatibility complex class II 
MOG:    Myelin oligodendrocyte glycoprotein 
MS:    Multiple sclerosis 
NFκB:   Nuclear factor kappa B  
NIK:    NFκB-inducing kinase 
NK:  Natural killer cell 
NKT:  Natural killer T cell 
PLP:    Proteolipid protein 
RAG:    Recombination-activation gene 
s.c.:   Subcutaneous 
SLT:    Secondary lymphoid tissue 
TCR:  T-cell receptor 
TGF-β:  Transforming growth factor-beta 
TH:    T-helper cells 
Tc:  Cytotoxic T cell 
TMEV-IDD: Theiler’s murine encephalomyelitis virus-induced demyelinating 
disease 
TNF-α:  Tumor necrosis factor alpha 
TLR:  Toll-like receptor 
Treg:    Regulatory T cell 
Wt:  Wild-type 
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SUMMARY 
 
Subcutaneuos immunization with protein antigen (Ag) leads to the licensing of local 
dendritic cells (DCs) and the initiation of T cell priming. At the site of immunization, 
DCs take up the antigen (Ag) and subsequently migrate into the regional lymph nodes 
where they initiate the activation and expansion of T cells recognizing their cognate 
Ag. The structural environment within secondary lymphoid tissues (SLTs) is 
considered essential for the initiation of adaptive immunity. However, we discovered 
that immunization-induced T cell priming can occur outside of such dedicated SLTs.  
While B cell priming is highly dependant on the topography of SLTs, effective T cell 
immunity can occur completely independent of lymphoreticular structures. In the 
absence of SLTs, the liver displays the potential to serve as an alternative site for T-
cell priming.  
After successful T cell priming occurred, T cells migrate through the body's tissues in 
search of their cognate Ag, which needs to be presented by an Ag-presenting cell 
(APC) in the context of major histocompatibility complex class II. When a self-Ag, 
such as CNS-myelin is the prime target, T cells re-encouter their cognate Ag 
presented by central nervous system (CNS)-associated DCs in perivascular spaces, 
which is an absolute requirement for the development of experimental autoimmune 
encephalomyelitis. After this second encounter with their cognate Ag, myelin-reactive 
T cells cross the glia limitans and enter the CNS parenchyma where they interact with 
CNS-resident microglia. Microglia do not serve as classical APCs, however they will 
produce a host of vasoactive substances, cytokines and chemokines leading to the 
invasion of other leukocytes and the development of a tissue lesion. While the precise 
molecular mechanisms of the disease pathogenesis will need to be elucidated in the 
future, our findings have provided a great leap of our understanding of the spatial and 
temporal process occurring during autoimmune diseases.  
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ZUSAMMENFASSUNG 
 
Subkutane Immunisierung mit Protein-Antigen führt zur Aktivierung von 
dendritischen Zellen (DCs) und T-Zell „priming“. Nachdem DCs das Antigen (Ag) 
lokal aufgenommen haben, migrieren sie in die regionalen Lymphknoten, wo sie die 
Aktivierung und Expansion von T Zellen induzieren, welche das Ag erkennen. 
Sekundäre lymphatische Organe (SLOs) mit ihren klar abgegrenzten T- und B-
Zellzonen werden als auschlaggebend für die Entwicklung adaptiver Immunität 
betrachtet. Wir haben jedoch entdeckt, dass Immunisierungs-induziertes T-Zell 
„priming“ auch ausserhalb von solch definierten Strukturen stattfinden kann. 
Während effektive B-Zellaktivierung von der Topographie in SLOs abhängig ist, 
funktioniert T-Zellaktivierung ohne lymphoretikuläre Strukturen. Wir haben 
herausgefunden, dass in der Abwesenheit von SLOs möglicherweise die Leber als 
Organ für T-Zell „priming“ dienen könnte.  
Nachdem T-Zell „priming“ erfolgreich stattgefunden hat, verlassen die T Zellen die 
SLOs um den Körper nach ihrem spezifischen Ag zu durchsuchen, das auf dem 
„major histocompatibility complex class II“ von Ag-präsentierenden Zellen (APZs) 
präsentiert weren muss. Wenn ein Selbst-Ag das Angriffsziel ist, wie z.B Myelin im 
Zentralnervensystem (ZNS), treffen die Myelin-reaktiven T Zellen im perivaskulären 
Raum auf DCs, welche ihnen ihr Ag präsentieren. Dieser Schritt ist absolut 
entscheidend für die Entstehung der experimentellen Autoimmun-Enzephalomeylitis. 
Nach der Wiedererkennung des Ags migrieren die Myelin-reaktiven T Zellen durch 
die Glia Limitans und dringen in das Parenchym des ZNS ein. Dort interagieren sie 
mit ZNS-angesiedelten Microgliazellen, die daraufhin aktiviert werden. Microglia 
dienen nicht als klassische APZs, sekretieren jedoch vasoaktive Substanzen, Zytokine 
und Chemokine, wodurch die Invasion von Leukozyten und die Entwicklung einer 
Läsion herbeiführt wird. Während die genauen molekularen Mechanismen des 
Krankheitsverlaufes zukünftig noch genauer untersucht werden müssen, haben unsere 
Daten einen grossen Erkenntnisgewinn im räumlichen sowie zeitlichen Ablauf 
autoimmuner Erkrankungen erbracht .   
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INTRODUCTION 
 
ADAPTIVE IMMUNITY AND AUTOIMMUNITY 
The mammalian immune system constitutes antigen (Ag)-non-specific innate 
immunity and Ag-specific adaptive immunity. Innate immunity comprises the first 
line of defense against pathogens whereby phagocytic cells (e.g. macrophages, 
neutrophils) and natural killer (NK) cells are considered key players in eliminating 
infections. A prime feature of innate immunity is its capacity to recognize a vast array 
of patterns shared by many pathogens through germline-encoded pattern recognition 
receptors (Toll-like receptors (TLRs)). While innate immune responses can act 
rapidly immediately after recognition of molecular patterns, adaptive immunity 
requires significantly more time to develop. These two arms of immunity are not 
separate entities but heavily intertwined and influence one another. Adaptive 
immunity is defined by Ag-specificity, diversity and immunological memory. While 
these features allow highly complex and specific immune recognition, adaptive 
immunity can also function improperly leading to the failure of self-non-self 
recognition and the development of allergies, asthma or autoimmune diseases such as 
multiple sclerosis (MS).  
Adaptive immune responses can be divided into cellular and humoral immunity. The 
humoral branch of the immune system comprises B cells which differentiate into 
antibody (Ab)-secreting plasma cells whereas the cellular immune response is 
characterized by T cells recognizing Ag presented on major histocompatibility 
complex (MHC) by antigen presenting cells (APCs). CD4+ T cells recognize Ags that 
are associated with MHC class II (MHCII) molecules, whereas CD8+ T cells bind Ag-
MHC class I (MHCI) complexes. “Professional” APCs such as dendritic cells (DCs) 
display the unique hallmark to initiate primary immune responses by Ag-presentation 
to naïve T cells (4,5). On the other hand, “non-professional” APCs like B cells are 
engaged in secondary T cell responses by Ag-presentation to primed T cells (6).  
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In this thesis I will discuss the role and function of secondary lymphoid tissues 
(SLTs) in the priming and activation of T lymphocytes, investigate how such T cells, 
when their cognate Ag is self-Ag, recognize their target in the central nervous system 
(CNS) and delineate the participation and function of microglia in regulating the 
events leading to the unleashing of an inflammatory cascade.  
 
EVOLUTION OF ADAPTIVE IMMUNITY AND THE ROLE OF PERIPHERAL 
LYMPHOID TISSUES  
 
EVOLUTION OF ADAPTIVE IMMUNITY 
In contrast to innate immunity, which exists in all vertebrates, invertebrates and to 
some extent in plants, adaptive immunity is only found in vertebrates and is 
characterized by lymphocytes, Ag-receptors (Abs and T-cell receptors (TCRs)), 
MHCI, MHCII and immunological memory (18). Adaptive immunity has evolved in 
the oldest jawed vertebrates (Gnathostomes such as cartilaginous fish including 
sharks) with the emergence of the unique recombination-activating gene (RAG), 
which rearranges Ag-binding receptors by somatic recombination. RAG is held to be 
the key feature of adaptive immunity as it creates a vast diversity of (non-germline 
generated) T and B cell receptors highly specific for limitless recognition of any 
biological molecule (19).  
Most of the jawless vertebrates (Agnathans) are extinct except for the lampreys and 
the hagfish. It has recently been reported that lampreys, which lack all lymphoid 
tissues, display adaptive immune responses executed with RAG-independent 
mechanisms. This new type of variable lymphocyte receptors (VLRs) is thought to be 
an ancestral prototype for adaptive immunity (20). It is assumed that with the 
evolution of a jaw in relation to a predatory life adaptive immunity was brought 
about. The jaw hypothesis states that adaptive immunity arose in the gastrointestinal 
region of primitive jawed fish (Placoderm) as a result of enhanced infections due the 
altered feeding behavior (21).  
After the emergence of T and B lymphocytes in jawed fish, the evolution of adaptive 
immunity has invented new specialized organs in higher vertebrates: Secondary 
lymphoid tissues (SLTs) such as lymph nodes (LNs). The micro-environment of SLTs 
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with the distinct T and B cell areas is considered essential for the sequestration of Ag 
and the initiation of T and B cell-mediated immunity. Interestingly, immunoglobulin 
(Ig)-class switching and germinal center (GC) formation, the site where B-cell 
differentiation into plasma and memory cells occurs, are lacking in cartilaginous fish 
and only appeared at the time of the divergence of amphibians (18). This observation 
would imply that cell-mediated immunity evolved earlier than “modern” humoral 
immune responses and raises the question whether productive T and B cell immunity 
requires the same structural environments. 
 
SECONDARY LYMPHOID TISSUES 
SLTs include LNs, the spleen, Peyer’s patches, gut- and bronchus-associated 
lymphoid tissues, and are considered essential for the development of adaptive 
immune responses. SLTs are greatly organized structures and have evolved in order to 
trap and concentrate Ag and to allow the interaction of Ag-laden APCs with rare Ag-
specific T and B cells. Prevailing immunological dogma dictates that only if the Ag 
reaches or is transported by APCs to SLTs an immune response is generated 
otherwise it is ignored by lymphocytes (22,23,24,25). The highly organized SLTs 
contain defined compartments consisting of T cell areas (partacortex in LNs and 
periarterial lymphoid sheath in the spleen) and B cell areas (cortex containing GCs) 
(Figure 1 and 2).  
 
 
 
 
 
 
 
 
 
 
Figure 1: Basic structure of a SLT. Modified and adapted from Aloisi et al. (26). 
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The paracortex is the site where circulating T lymphocytes enter the LN and interact 
with Ag-laden DCs. T lymphocytes specific for the foreign Ag are thus activated and 
clonally expand. Upon differentiation, T cells either leave the LNs in order to migrate 
through the body’s tissues in search of their cognate Ag displayed by resident APCs 
or they home to the B cell areas to assist in Ag-specific Ab production. After 
receiving T cell help, which initially takes place in the paracortex, activated B cells 
migrate together with TH cells into the cortex in order to initiate the GC reaction (27). 
In GCs, a network of follicular dendritic cells (FDCs) displays Ag-Ab complexes to B 
cells. FDCs are reticular fibroblasts (non-lymphocytic cells) specialized to promote B 
cell survival and proliferation. The interaction of B cells with FDCs and TH cells is a 
prerequisite for their differentiation into plasma cells and the production of high-
affinity Abs. In contrast to the cortex, T cell areas are structurally ill-defined. While 
intravital confocal microscopy has provided compelling evidence for the capacity of 
SLTs to host T cell priming (28,29), definitive data supporting their absolute 
requirement for functional T cell priming is lacking.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Pathway of B cell differentiation. Adapted and modified from Mackay et al. (27). 
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TERTIARY LYMPHOID TISSUES 
Ectopic lymphoid neogenesis can develop upon chronic inflammation such as an 
autoimmune response or infection. The micro-architecture of these tertiary lymphoid 
structures (TLTs) resembles SLTs as they contain defined T cell and B cell 
compartments. TLTs have been described in humans e.g. for myasthenia gravis in the 
thymus, chronic hepatitis C in the liver or MS in the CNS (26). Such lymphoid-like 
structures found in MS patients were located in the meninges and comprise B cells, T 
cells and FDCs. It is thought that for the formation of both SLTs and TLTs the same 
signaling components are required. These include mainly signaling through 
lymphotoxin β-receptor (LTβR). In mice, transgenic expression of LTα in the 
pancreas induced the chronic infiltration of lymphocytes and the development of 
TLTs (30). However, ectopic neogenesis might depend on additional signaling 
pathways other than LTβR signaling. This is shown by the fact that splenectomized 
LTα-/- mice, which lack all SLTs, were able to induce lymphoid neogenesis (31). For 
the recruitment of B cells, T cells and DCs, the expression of the chemokines CCL21, 
CCL19 and CXCL13 is further implicated to play a critical role (26). The underlying 
cause for the formation of TLTs remains speculative. In chronic inflammations the 
development of TLTs might exacerbate the disease. However upon infections with 
pathogens, TLTs could provide a benefit for the host and might even replace 
conventional SLTs. 
 
ALYMPHOPLASIA MICE  
The role of NFkB-inducing kinase  
The nuclear factor κ B (NFκB) family of transcription factors induces the expression 
of a vast variety of genes involved in innate and adaptive immune responses, 
activation, development, cell growth and apoptosis (32). The activation of NFkB is 
tightly regulated and its constitutive expression has been associated with 
inflammatory diseases such as rheumatic arthritis and MS. In mammals, 5 different 
members exist which can form homo and heterodimers: NFkB1 (p50 and its precursor 
p105), NFkB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel. The 
prominent activated form comprises the heterodimers p65 with p50 or p52. They are 
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retained in an inactive form in the cytoplasm by inhibitory IkB proteins which mask 
their nuclear localization signal (NLS) (33).  
Two NFkB pathways exist: The canonical pathway includes NFkB1 and RelA, and 
the non-canonical pathway involves NFkB2 and RelB (Figure 3). The classical 
pathway is activated by inflammatory stimuli (such as TNF-α and lipopolysaccharide 
(LPS)) through TNF receptors (TNFR), TLRs, and IL-1 receptors leading to the 
activation of IkB-Kinases (IKKs). The IKK complex consists of IKK1, IKK2 and 
IKK3 and upon activation, phosphorylates IkB proteins leading to their proteosomal 
degradation and thus activation and translocation of NFkB1/Rel-A into the nucleus. 
Members of the non-canonical pathway include CD40, LTβR, receptor activator of 
NF-kB (RANK) and B-cell activating factor receptor (BAFFR).  This pathway is 
dependent on IKK1, but independent of IKK2 and IKK3. The crucial component is 
the NFkB inducing kinase (NIK) which activates IKK1 that in turn phosphorylates 
and processes p100, releasing the active form of NFkB2/Rel-B (p52-RelB) to 
translocate into the nucleus and activate gene transcription. 
 
 
 
 
 
 
 
 
 
 
 
      
        Figure 3: NFκB signaling pathways. Adapted and modified from Youssef et al.  (34). 
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Alymphoplasia mice 
Alymphoplasia (aly/aly) mice are characterized by a complete lack of LNs and Peyer's 
patches due to a point mutation in NIK (35,36,37,38). The spleen of aly/aly mice is 
devoid of well-defined lymphoid structures and the thymus does not display discrete 
borders between the cortex and the medulla. LTβR-/- and NIK-/- mice exhibit similar 
developmental defects as aly/aly mice (38,39). In addition to the lymphoid 
malformations caused by the disrupted LTβR-signaling, aly/aly mice are also 
immuno-deficient. This became evident by the fact that the development of GCs, 
isotype-switching and affinity maturation is entirely abolished. The serum levels of 
IgG and IgA in aly/aly mice are virtually absent while the amount of IgM is one third 
in comparison to control mice (24). In splenectomized aly/aly mice the Ab response is 
completely ablated (40).  
Aly/aly mice are not able to reject allogeneic skin grafts (24,41) while splenectomized 
aly/aly mice accept vascularized organ transplants indefinitely suggesting that 
allograft responses to vascularized organs are not initiated in the graft itself but rather 
in SLTs. Moreover rejection of tumors in aly/aly mice was abrogated, which was 
attributed to the fact that tumor cells cannot be trapped in LNs in order to induce 
priming of CTLs (42). 
Aly/aly mice are highly susceptible to viral infections such as vesicular stomatitis 
virus (VSV) due the absent Ab switch to the protective IgG. Injections with 
lymphocyte choriomeningitis virus (LCMV) and vaccinia virus (VV) resulted in 
delayed elimination or life-long persistence of the virus respectively (43). The 
structural malformations were considered the underlying cause for this inefficient T 
and B cell cooperation.  This notion was further supported by using BM-chimeric 
mice, which revealed that the weak CTL-response to LCMV in aly/aly mice is caused 
by the absence of LNs and not from an intrinsic T cell defect. However, for B cells an 
intrinsic defect independent of SLTs was found (44). Garceau et al. have shown that 
NIK is essential for T cell dependant B cell maturation through CD40 but that NIK 
signaling upon CD40 engagement is dispensable for the activation of DCs (37).  
Recently it has been discovered that NIK itself is vital for T cell activation in general 
and in the context of autoimmunity. NIK-deficient T cells displayed reduced 
proliferation and IL-2 production in response to TCR cross-linking (45). Sprent and 
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coworkers explained these T cell defects in aly/aly mice (46) with the action of a new 
identified subpopulation of memory CD4+ T cells (CD25- foxp3-) which mediated 
immuno-suppression. When this inhibitory population was removed, naïve aly/aly T 
cells showed hyper-responsive proliferation to T cell receptor (TCR)-CD28 ligation. 
Adoptive transfer of such hyper-responsive naïve aly/aly T cells (depleted of 
suppressive T cells) into recipient mice (RAG-/-) caused the development of 
autoimmune disease. The hyper-responsiveness was attributed to reduced p100 
synthesis leading to unregulated nuclear translocation of NFkB1. Therefore the 
NFkB2 signaling pathway including NIK might acts as a regulatory brake for the 
NFkB1 pathway. 
 
DENDRITIC CELLS: PROFESSIONAL APCS AND REGULATORS OF 
IMMUNE RESPONSES  
 
DCs are the most powerful APCs in higher vertebrates and conduct major control 
over the development of an immune response. The immunological outcome of 
immunity is mainly influenced by their activation state. Upon exposure to microbial 
products, DCs induce immunity whereas in the steady state, they are critical for the 
maintenance of tolerance.  
As the “sentinels” of the immune system, DCs reside as immature cells in peripheral 
tissues in constant search of pathogens. Ags are captured by DCs through receptor-
mediated endocytosis via C-type lectins (e.g. DEC-205), Fcγ receptors or non-
specifically through macro-pinocytosis or phagocytosis. Internalized Ag is processed 
in acidic endocytic compartments by proteases and subsequently displayed in 
association with MHCII molecules on the surface of the cell (7,8). Ag capture and 
maturation stimuli (inflammatory mediators and microbial products) induce the 
differentiation from the immature Ag-capturing cell to a mature APC. Mature DCs 
downregulate their endocytic capacities, upregulate Ag-MHCII complexes and 
costimulatory molecules (e.g. CD40, CD80 and CD86). The expression pattern of 
chemokine receptors necessary for migration is subsequently changed. CCR7  enables 
DCs to migrate into the T cell zone of SLTs (9), CCR5 is important for the 
recruitment of DCs into inflammatory sites (10) and CCR6 plays a role for migration 
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to epithelial cell surfaces (11). For the initiation of T cell responses, the migration of 
DCs into SLTs is thought to be obligatory. There, DCs present Ag to T cells leading 
to their activation and expansion. The differentiation of naïve T cells into effector 
cells is dependent on the cytokines secreted by activated mature DCs.  IL-12 and IL-
18 promote the differentiation into CD4+ TH1 cells, on the other side the release of IL-
23 mediates the polarization to CD4+ TH17 cells. 
In addition to the Ag-specific priming of helper (TH) and cytotoxic (TC) T cells, DCs 
can activate innate protective cells such as NK cells or natural killer T (NKT) cells. 
An extensive array of pathogens is recognized by DCs through “innate” TLRs (12), 
which trigger their cytokine production (e.g. IL-12, IFN-α) as well as maturation 
necessary for the communication between innate and adaptive immunity. IL-12 
secretion by DCs stimulates NK cells to release IFNγ and increases NK-cell 
cytotoxicity (13). TNF-α produced by NK cells on the other hand influences DC 
maturation. Thus DCs form an essential link between innate and adaptive immune 
responses. 
 
TOLERANCE VERSUS AUTOIMMUNITY  
Central tolerance in primary lymphoid organs during early maturation of lymphocytes 
leads to the deletion of self-reactive T cells (in the thymus) and B cells (in the bone 
marrow (BM)). This mechanism is however incomplete and cells recognizing self 
components can escape negative selection which may cause the development of 
autoimmune diseases. MS is an example of such an inappropriate cellular immune 
response directed against myelin components of the CNS (see page 17, “Multiple 
sclerosis”). This inflammatory autoimmune disease is thought to be mediated by 
myelin-reactive T cells, which have escaped tolerance.  
In order to silence auto-reactive cells, a “back-up” mechanism in the periphery exists 
termed peripheral tolerance. It is widely accepted that tolerogenic DCs are the 
primary mediators of peripheral tolerance (14). Tolerogenic DCs resemble immature 
DCs whereby the common features are the low expression of MHCII, CD40 and 
CD80/86 due to the absence of inflammatory molecules and “danger signals” (15). 
Peripheral tolerance is brought about through different mechanisms. Tolerogenic DCs 
can induce the deletion of reactive T cells, render them unresponsive (anergy) or 
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initiate the differentiation into regulatory T cells (Tregs). The release of 
immunosuppressive cytokines such as IL-10 and TGF-β by tolerogenic DCs drives 
the development of IL-10 producing Tregs. Collectively, the current view is that 
mature DCs control immunity to Ags and immature DCs tolerize T cells to self-
antigens which is essential to prevent autoimmunity. 
 
DENDRITIC CELL SUBTYPES AND FUNCTIONS 
Different subtypes of DCs exist which can be distinguished by their cell-surface 
markers, their various functional properties, their location and their cytokine 
production. In mice, the two main subtypes are designated lymphoid and myeloid 
DCs (16). Lymphoid DCs are characterized by CD8α expression whereas the myeloid 
DCs are defined by the marker CD11b. Both subpopulations express CD11c, are 
capable of Ag-uptake and presentation to T cells. It remains unclear whether the 
distinct DC subtypes derived from the same or different hematopoietic lineages 
(16,17) and how their functional differences might reflect the polarization of an 
immune response. Lymphoid DCs produce higher levels of IL-12 and skew CD4+ T 
cells to the production of TH1 cytokines. On the other hand, myeloid DCs prime CD4+ 
T cells to produce TH2 cytokines (7) and are more phagocytic than lymphoid DCs. 
Lymphoid DCs are often implicated in regulatory T cell responses (14). It is not 
clearly established whether different DC subpopulations have the capacity to induce 
immunity or tolerance only depending on their maturation state or whether a 
specialized tolerogenic DC type exists. Despite the distinct functions by various DC 
subsets, they exhibit considerable plasticity and redundancy in driving immune 
responses. 
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THE PATHOGENESIS OF CNS-AUTOIMMUNE DISEASES 
 
MULTIPLE SCLEROSIS 
MS is the most common autoimmune disease of the central nervous system (CNS) 
and 1 in 900 individuals is affected in Switzerland. MS is characterized by 
inflammation, demyelination and axonal loss in the white matter. Although the 
etiology of MS remains to be established, the most widely accepted view is that 
immune tolerance to self (myelin) is broken, which results in the expansion of myelin-
reactive T cells and their migration into the CNS. The disease is thought to be 
mediated by CD4+ T cells auto-reactive against components of the myelin sheath (47). 
This notion is supported by the histopathologic observations of the presence of 
activated T cells in the perivascular spaces of inflammatory lesions (sites of 
demyelination). These infiltrates correspond to the lesions seen with magnetic 
resonance imaging (48,49,50) and were detected in the periventricular white matter, 
brain stem, cerebellum and spinal cord white matter.  
The disease is most prevalent in young adults of Caucasian heritage with female 
preponderance (sex ratio female:male is 1.8). MS can be classified into 3 clinical 
subtypes: Primary progressive, secondary progressive or relapsing-remitting while the 
latter is the most frequent form. Common clinical features comprise paralysis, visual 
impairment, sensory disturbances and fatigue. It is widely believed that genetic 
factors may play a critical role in the susceptibility to the disease. Certain genes 
linked to the human leukocyte antigen (HLA) complex were found to exert an 
influence on the pathogenesis of MS (HLA-DR, HLA-DQ, TNF-α). A current view is 
that the myelin attack could be triggered by microbes and virus (e.g. Epstein-Barr 
virus) which proteins share homologies to myelin proteins. This concept is termed 
molecular mimicry. 
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EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS  
Experimental autoimmune encephalomyelitis (EAE) serves as the animal model for 
MS and can be induced in susceptible rodent strains by subcutaneous (s.c.) 
immunization with myelin Ags such as myelin oligodendrocyte glycoprotein (MOG), 
myelin basic protein (MBP) or proteolipid protein (PLP).  
The fact that the disease can be transferred from one animal to another by the 
adoptive transfer of encephalitogenic CD4+ T cells supports the notion that EAE is 
mainly mediated by the actions of CD4+ T cells (51). The role of CD8+ T cells 
remains controversial (52,53). While several groups could clearly demonstrate that 
CD8+ T cells restricted to an MHCI myelin Ag can transfer EAE (54,55,56), the lack 
of CD8+ T cells in actively immunized mice worsens EAE development (57,58) .  
Studies of the EAE model have helped define the sequence of immunopathological 
events involved in the development of autoimmune CNS-directed inflammatory 
disease. This sequence can be sub-divided into two major phases: T cell 
priming/activation and effector phase. At the site of immunization, local DCs capture 
myelin Ags and subsequently migrate from non-lymphoid peripheral tissues through 
afferent lymphatics into the draining LNs (7,8). Microbial adjuvants administered 
with the vaccine (e.g. Mycobacterium Tuberculosis in Complete Freund’s adjuvant) 
induce the maturation of DCs which are then licensed to initiate the activation and 
expansion of neuroantigen-reactive T cells within SLTs (47). In the subsequent 
recruitment and effector phase, activated myelin-reactive T cells migrate to the CNS 
where they re-encounter their cognate Ag, in the context of MHCII molecules (59,60). 
After a few days a substantially increased number of activated T cells enter the CNS, 
fostering subsequent T cell migration deeper into the CNS parenchyma (61). They can 
now cause tissue destruction leading to, depending on the model, demyelination and 
ultimately neurologic deficit. During this phase, microglial cells are thought to 
provide additional Ag-specific as well as MHC- independent signals for invading 
inflammatory T cells.  
 
Melanie Greter     Dissertation 2007  INTRODUCTION 
 
19 
Encephalitogenicity 
Upon activation by APCs, CD4+ TH cells can differentiate into distinct subsets 
depending on their cytokine environment. TH1 cells are characterized by their IFNγ, 
IL-2 and TNF-α secretion, TH2 cells produce IL-4, IL-5, IL-10 and IL-13. In general, 
TH1 cells regulate cell-mediated immunity whereas TH2 cells mediate humoral 
immune responses. One subset can promote the differentiation of its own subset while 
the development of the other subset is antagonized. TH1 cells were proposed to induce 
organ-specific autoimmunity and have been implicated in the pathogenesis of EAE 
and MS (62). Conversely, TH2 cells can suppress EAE and MS, although they may 
exacerbate these diseases in immuno-compromised hosts (63). Thus, the final 
composition of the TH cell response to Ag determines whether the outcome of 
infectious, inflammatory and autoimmune responses is beneficial or detrimental.  
The TH1/ TH2 concept has recently undergone a significant paradigm shift. This shift 
was brought about by the observation that the lack of the major TH1 cytokine IFN-γ 
exacerbated the disease (64) and renders even resistant mouse strains EAE-
susceptible (65,66). Furthermore, the most critical cytokines promoting TH1 
polarization are IL-12 and IL-18, which are both predominantly secreted by activated 
DCs and monocytes/macrophages. Mice lacking IL-12 (p35-/-) were shown to be 
hyper-susceptible to EAE (67,68,69). IL-18-/- mice as well as IL-12-/-/ IL-18-/- double 
knock-out mice develop EAE with the same disease severity and kinetics as wild-type 
(wt) mice (70). The discovery that p40-/- mice are resistant to EAE has led to the 
identification of a new cytokine IL-23 which promotes a novel CD4+ TH subset 
distinct from TH1 and TH2 (TH17). IL-23 consists of the unique p19 subunit and the 
common p40 subunit which is shared with IL-12. IL-23 is considered the crucial 
cytokine for the development of autoimmune diseases such as EAE or collagen-
induced arthritis (71,72,73). While IL-23 is responsible for the maintenance of these 
diverse inflammatory IL-17-producing CD4+ T cells, de novo generation depends on 
the presence of IL-6 and TGF-β in vitro (74). On the other hand, IL-27 was shown to 
suppress the development of TH17 cells (75). 
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THE BLOOD BRAIN BARRIER AND THE IMMUNE PRIVILEGE OF THE CNS 
The CNS is often referred to as a site of limited immune surveillance. This concept 
dates back to the seminal work of Medawar (76) and Barker & Billingham 
demonstrating that allografts fare better in the CNS compared to other tissues (77,78). 
It was also commonly assumed that the CNS is rare of leukocytes and its 
“immunologically privileged” status has for long been attributed to the blood-brain 
barrier (BBB) and the lack of classic lymph vessels. The model of a BBB describes a 
mechanical diffusion barrier for hydrophilic molecules (including Abs and 
complement) to selectively separate the blood from the CNS parenchyma. The BBB is 
formed by specialized tight junctions of endothelial cells of the vessel wall which are 
surrounded by astroglial endfeet forming the glia limitans (79). The space between the 
blood vessel and the glia limitans is termed Virchow-Robin space or perivascular 
space (Figure 4). The function of the BBB is thought to restrict lymphocyte 
infiltration in order to prevent the development of an inflammatory response and 
neuronal damage. Infection of peripheral tissues with LCMV in mice usually induces 
a massive expansion of virus-specific CD8+ T cells, which results in efficient viral 
clearance (80). When the virus is inoculated directly to the CNS, however, it causes a 
lethal disease lacking CD8+ T cell infiltration (81,82). Hence in the case of infection, 
the CNS appears to be a defenseless victim at the mercy of the peripheral immune 
system to control or end the attack. From an evolutionary point of view, it may in fact 
be less detrimental for an individual to tolerate certain neurotropic viruses (such as 
varicella zoster) than the elimination of all infected neurons (83,84).  
 
 
 
 
 
 
 
            
             
             Figure 4: Topography of the perivascular space. 
               Adapted and modified from Bechmann et al. (79,1) 
Melanie Greter     Dissertation 2007  INTRODUCTION 
 
21 
The previous definition of an “immune-privileged” CNS was challenged by various 
studies. It became apparent that the CNS is within constraints to immune cells in 
regards to the delicate balance of costs over benefits during neuroinflammation. 
Leukocytes readily cross brain endothelial cells to reside in perivascular spaces or 
move on into the CNS parenchyma (85,84,86). It is also established that Ags 
efficiently drain into cervical LNs via the cribroid plate and perineural sheath of 
cranial nerves (87). Recent data suggest similar routes for APCs (88,89,90) (see also 
page 24, “CNS-associated dendritic cells – sentinels at the gateway to the CNS”). The 
immune-privilege of the CNS is therefore not absolute but crucial to limit 
neuroinflammation and neurodegeneration in a tissue of vital importance in which 
regeneration is limited.  
 
ANTIGEN PRESENTATION AND TARGET RECOGNITION IN EAE 
After immunization-induced expansion of encephalitogenic TH cells in the systemic 
immune compartment, these T cells are now equipped to leave the lymphoreticular 
environment and invade the bodies' tissues scanning for APCs presenting their 
cognate Ag. Oligodendrocytes are ultimately the target of such TH cells. They are the 
CNS’ myelinating cells wrapping their cell membranes around axons to provide nerve 
insulation for optimal conductivity. However, while oligodendrocyte loss and 
demyelination are ultimately seen in EAE, oligodendrocytes cannot directly be 
recognized by CNS invading T cells as they are incapable of expressing MHCII 
molecules (91). A compulsory third party APC is an absolute requirement for 
encephalitogenic TH cells to recognize myelin Ag within the CNS. Cerebral 
microvascular endothelial cells, which are part of the BBB, are not considered as 
APCs (92) since they do not constitutively express MHCII molecules and fail to 
induce T cell proliferation in vitro (92,92). Whether astrocytes, the major glial 
population within the CNS, mediate APC-T cell interaction and activation is a lively 
controversy (93,94,95). Although astrocytes display the functional capacity to present 
Ag in vitro, their contribution as APCs to the pathogenesis of EAE remains unlikely. 
The cell type and location of the APC mediating T cell entry into the CNS has so far 
remained unknown. CNS-resident cells (microglia) or CNS-associated cells (DCs and 
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macrophages at the BBB) represent ideal candidates to potentially present myelin 
epitopes to infiltrating T cells and will be discussed in detail below. 
 
MICROGLIA – SENTINELS OF THE CNS PARENCHYMA 
Glial cells were initially defined as the glue (greek: glia) keeping the neurons in the 
brain together (96). In 1932 the neuropathologist del Rio Hortega described a third 
type of glial cells in addition to astroglia and oligodendroglia, later named microglia 
(97). Microglia comprise about 10% of the total glial population in the CNS 
parenchyma (96) and are in contrast to the other cells residing in the CNS 
parenchyma not of neuroectodermal but of mesodermic origin. The most widely held 
hypothesis is that during embryogenesis, early monocyte precursor cells migrate from 
the yolk sac into the developing CNS where they differentiate into parenchymal 
microglial cells (98). Unlike the CNS-associated phagocytes of the leptomeninges and 
the perivascular spaces, microglia are not readily repopulated by bone marrow (BM)-
derived monocytes during adulthood (99). But there is evidence for regional turnover 
at low rates and rapid transformation of blood monocytes into microglia during 
pathologies (100,84). Microglial cells are regarded as the resident macrophages of the 
CNS and indeed they share many properties with them, having developed from a 
common precursor cell. Microglia are rapidly activated from their quiescent state to 
any pathological change in the CNS such as inflammation, infections, injuries, 
neurodegeneration and tumors (101). Their ability to respond to a vast array of stimuli 
is considered vital for the first line of defense of the CNS. Nevertheless their 
uncontrolled activation, release of inflammatory cytokines (such as IL-1, IL-6 and 
TNF-α) and neurotoxic molecules in many CNS diseases are implicated to account for 
unspecific tissue damage.  
Microglia are not only involved in phagocytic functions but are also thought to 
participate in Ag-presentation which is displayed by the rapid upregulation of MHCII 
and the costimulatory molecules in response to virtually all inflammatory conditions 
(102,103,104). Microglia, like CNS-associated cells, phagocytose myelin 
(105,106,107), indicating that these cells could potentially present Ag and activate 
myelin-specific CD4+ T cells thus causing specific tissue damage.  
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Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease 
(TMEV-IDD) serves as an animal model for MS and is characterized by persistent 
TMEV infections of microglial cells and the chronic progressive CD4+ T cell-
mediated demyelination (108). It was shown in vitro that microglial cells isolated 
from TMEV infected mice were activated to efficiently process and present not only 
endogenous viral epitopes but also exogenous myelin epitopes to CD4+ T cells 
(109,110).  
Human microglia, either immediately ex vivo or cultured for several days, have been 
reported to act as APCs, and to induce both primary and secondary proliferative T-
cell responses (111,102). Similar APC potential was also demonstrated for rat 
microglia isolated from neonatal brains (112,95), but in these studies, extraneural, 
leptomeningeal and perivascular CNS-associated APCs were not separated from 
microglia and may contribute to T cell activation. Recent reports have raised the 
concern whether such neonatally-derived cells faithfully represent the adult 
population in vivo. In fact, microglia isolated from adult mice fail to present Ag to 
naïve Ag-specific CD4+ T cells (113), but those that are pretreated with IFNγ or 
isolated from EAE-diseased mice can activate T cell lines in an Ag- and CD86-
dependent manner in vitro (114).  
The activation and differentiation of CD4+ T cells require MHCII recognition and co-
stimulation. Studies using adoptive transfer of primed myelin-reactive CD4+ T cells 
into mice in which APCs can no longer deliver a specific co-stimulatory signal have 
identified CD40, CD80/CD86 and CD134 (OX40) as functional for reactivation of 
these T cells in the CNS (115,116). Recent work using BM-chimeric mice pinpointed 
the primary source of these costimulatory molecules in the CNS. BM-chimeric mice 
in which CD40 is deficient only in microglia but is intact in CNS-associated cells has 
revealed that microglial CD40 is most critical to the reactivation of peripherally 
primed encephalitogenic T cells and the progression of EAE (117). Infiltrating T cells 
expressing CD40 ligand (CD154) can stimulate microglial CD40 to upregulate IL23 
which in turn drives IL-17A expression by these encephalitogenic CD4+ T cells. 
Whether microglia participate in the onset and maintenance of MS/EAE or may also 
play a role in tissue repair via the actions of neurotrophic and immunosuppressive 
factors is a subject of debate. It is likely that microglia are capable to regulate the 
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expansion of encephalitogenic T cells within the CNS. CNS-APCs derived from 
EAE-diseased mice were found to inhibit T cell proliferation through the release of 
toxic levels of nitric oxide (118). In addition, isolated microglia from EAE mice were 
shown to induce T cell apoptosis through Fas-Fas ligand interaction (88,119). In line 
with this findings, many T cells in the CNS of rodents with EAE undergo apoptosis 
within the parenchyma (120), where they are in contact with microglia.  
For a long time, microglia have appeared to be the most capable APCs to initiate and 
sustain a T cell-mediated immune response within the CNS (121). However until now 
there has been no in vivo evidence for their capacity to act as APCs to allow T cell 
target recognition. 
 
CNS-ASSOCIATED DENDRITIC CELLS - SENTINELS AT THE GATEWAY TO 
THE CNS 
The “immune privilege” which is essential to guard the CNS from invading immune-
mediated damage, does not apply to non-parenchymal regions of the brain such as 
ventricles, meninges or subarachnoid spaces (88). Foreign tissue grafts are eliminated 
when they are injected into the ventricles and tumors can be rejected when they are 
located near the ventricles (122,123). It was shown by Matyszak and Perry that 
injection of the pathogen Bacillus Calmette-Guerin (BCG) to the meninges, but not 
the CNS-parenchyma, provokes a typical inflammation and a BCG Ag-specific T cell 
response (124). These examples clearly show that immunity within the CNS does 
occur and suggest the presence of specialized APCs at the portals to the CNS 
mediating immune responses. Indeed, although it has long been thought that the CNS 
is devoid of professional APCs, DCs and macrophages were found to be present in the 
healthy human and rat CNS. They are located in the perivascular spaces, the choroid 
plexus and the meninges but are absent from the CNS parenchyma under 
physiological conditions (125,126,127). These CNS-associated APCs seem 
strategically positioned to mediate immune surveillance and interaction with the 
immune system. 
In contrast to microglia, under steady state conditions, CNS-associated cells are 
continuously replenished by bone marrow-derived monocytes (128,99). Their 
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numbers drastically increase upon infections, autoimmune diseases or injuries 
(129,130). These various pathological conditions lead to DC activation and even 
migration into the CNS-parenchyma. Aloisi et al. demonstrated that DCs were 
recruited into the CNS parenchyma during EAE and hypothesized that they are a 
fundamental component for the onset and progression of the disease (126). CNS-
associated DCs constitutively express high levels of MHCII. Both in vitro and in vivo 
studies strongly point to the CNS-associated cells, rather than the microglia, as 
competent APCs (120). When isolated from adult rodent CNS, they were, in 
comparison to parenchymal microglia, more efficient in activating both naïve and 
primed CD4+ T cells (131,88,119).  
Using different MHCII restricting T cell elements, Hickey and Kimura could show 
that perivascular APCs –"considered to be macrophages” are sufficient to provide 
stimulatory signals for T cells to infiltrate the CNS. However, in order to induce EAE, 
the rats were required to develop graft vs. host disease (132) and thus changing the 
inflammatory environment and infiltrates of the CNS.  
CNS-associated DCs seem ideally positioned for influencing T cell trafficking to the 
CNS parenchyma. When they are depleted, lymphocyte invasion into the CNS 
parenchyma is blocked and EAE is prevented (133). They may engage in de novo 
processing of CNS Ags for in situ activation or tolerance induction of 
effector/memory as well as naïve T cells. In fact, Ag-recognition in perivascular 
spaces was proposed to be required for T cells to migrate into the CNS parenchyma 
across the BBB (134). Upon Ag capture in the CNS, CNS-associated APCs are likely 
to travel into cervical LNs in order to prime T cells. It was shown that Ag-loaded DCs 
injected into the CNS migrate into cervical LNs where they initiated primary immune 
responses (90). In patients with relapsing-remitting MS, myelin-ingested APCs were 
abundant in cervical LNs (135). Moreover, cervical LNs of marmoset and rhesus 
monkeys immunized with only MOG, contained an accumulation of APCs that had 
engulfed other myelin antigens, such as MBP and PLP (136).  
A recent study in which MS-patients were treated with a monoclonal Ab against very 
late antigen 4 (VLA4), demonstrates that restricting the CNS' immune surveillance 
could potentially lead to out-of-control expansion of pathogens such as the normally 
well controlled JC virus (human polyoma virus) (137). Therefore, under physiological 
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conditions, CNS-associated APCs are likely to be vital for the maintenance of 
peripheral tolerance. Under pathological conditions, the action of CNS-associated 
APCs seems absolutely essential for the immune invasion of the CNS. However, for 
CNS-mediated autoimmune diseases, definite in vivo data supporting the concept that 
CNS-associated DCs are the culprits to mediate T cell entry are lacking.  
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Subcutaneous immunization delivers antigen (Ag) to local Ag-presenting cells 
which subsequently migrate through afferent lymphatics into draining lymph 
nodes. Here, they initiate the activation and expansion of lymphocytes specific 
for their cognate Ag. In higher vertebrates, the structural environment within 
secondary lymphoid tissues (SLTs) is considered essential for the initiation of 
adaptive immunity. We could demonstrate, that the immunodeficiency observed 
in such alymphoplastic mice results exclusively from the impact of the genetic 
lesion on immunity rather than from the lymphoreticular malformations. 
Surprisingly, we discovered that in mice lacking all SLTs, subcutaneous 
immunization with foreign as well as auto-Ag can initiate productive T cell 
immunity as well as autoimmune disease respectively. While B cell maturation is 
highly dependent on the topography of SLTs, potent T cell priming can occur 
completely independent of lymphoreticular structures. Our data point towards 
the adult liver as a potential priming site for T cells after subcutaneous 
immunization. 
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SLTs are highly organized structures with defined compartments consisting of B cell 
areas (cortex containing germinal centres (GCs)) and T cell areas (paracortex in 
lymph nodes (LNs) and periarteriolar lymphoid sheaths in the spleen). These distinct 
locations support the rapid circulation and concentration of Ag and the interaction of 
Ag-presenting cells (APCs) with lymphocytes. Prevailing dogma dictates that only if 
competent APCs transport the Ag into SLTs, an adaptive immune response is 
initiated; otherwise the Ag is ignored by the immune system 1, 2. For the initiation of 
humoral immunity, the formation of B cell follicles and GCs is a prerequisite. GCs 
comprise networks of follicular dendritic cells (FDCs) which play a vital role in the 
generation of a high affinity antibody (Ab)-response. However, in contrast to the 
cortex, T cell areas, where T cells encounter mature APCs, are structurally rather ill-
defined. While intravital confocal microscopy has provided compelling evidence for 
the capacity of SLTs to host T cell priming 3, 4, definitive data supporting their 
absolute requirement for functional T cell priming does not exist. 
Alymphoplasia (aly/aly) mice are characterized by a complete lack of LNs and peyer's 
patches and structural alterations of the spleen and thymus due to a point mutation in 
the NFκB-inducing kinase (NIK) 5. NIK is vital for the initiation of the non-canonical 
NFκB cascade, which appears to play a discrete role in the function of CD40 and 
lymphotoxin-β receptor (LTβR) signaling in some cell types6-8. Aly/aly mice display 
impaired Ab responses and cannot reject allogeneic grafts or tumors 9-11. The lack of 
LNs is considered to be responsible for this apparent immunodeficiency 10, 12, 13. The 
developmental deficits in aly/aly mutants are readily explained by the requirement of 
NIK in LTβR signaling. LTβR-/- mice display similar developmental defects as do 
aly/aly mice or NIK-/- mice 8, 14. Others argued that the immunodeficiency in aly/aly 
mice could not be explained solely based on their developmental malformations 15. 
Here we demonstrate that immunization-induced T-cell priming and cell-mediated 
autoimmunity can be induced even in the absence of conventional SLTs. Conversely, 
B-cell maturation and Ab-class switching is structure-dependent and is completely 
abrogated in mice lacking SLTs indicating that modern mammalian B cells rely on the 
topography of dedicated lymphoid tissues, while T lymphocytes retain the capacity to 
recognize Ag in a structure-independent fashion. 
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RESULTS 
T cell priming and DTH reactions after subcutaneous immunization with protein 
Ag in the absence of LNs 
We wanted to elucidate the impact of the aly mutation on the development of a T cell-
mediated immune response induced by subcutaneous (s.c.) immunization. We used 
Keyhole limpet hemocyanin (KLH) as a model foreign Ag to elicit delayed-type 
hypersensitivity (DTH) responses. Aly/aly as well as aly/+ mice (the latter developing 
normal SLTs as NIK is not haplo-insufficient) were immunized with KLH and 11 dpi, 
they were challenged by intradermal injection with KLH into the ear. As illustrated in 
Fig. 1a, aly/aly mice were able to mount a solid DTH reaction measured by ear 
swelling, which was only marginally lower than in aly/+ mice. However, in contrast 
to ear-swelling, which is indicative of a T cell response, aly/aly mice did not mount 
Abs against KLH when compared to aly/+ mice demonstrating that the development 
of a humoral immune response is ablated in the absence of lymphoreticular structures 
(Fig. 1b). We could reproduce functional DTH responses using other Ags including 
Ovalbumin and myelin oligodendrocyte glycoprotein peptide (MOG35-55). 
In order to quantify the expansion of Ag-specific T cells in aly/aly mice, CFSE-
labeled T cells derived from TcR transgenic mice (2D2) 16 were adoptively transferred 
into either aly/aly or aly/+ mice prior to immunization with their cognate Ag (MOG35-
55). After 4 days, splenocytes were analyzed for T cell expansion by flow cytometry 
(Fig. 1c). Although Ag-specific T cell expansion can be observed in aly/aly mice, 
primed T cells undergo fewer cell divisions in aly/aly mice than in aly/+ mice. In 
support of the notion that this delayed response could be attributed to the lack of LNs 
in aly/aly mice, in alymphoplastic LTα-/- mice, antiviral T and B cell responses also 
display delayed kinetics 17. Similar results were obtained with OVA-TcR transgenic 
cells (OTII) transferred into aly/aly and aly/+ mice (not shown). 
The aly mutation prevents the development of autoimmune disease 
We next wanted to assess whether the unexpected observation of effective T cell 
immunity in mice lacking LNs can be reproduced in a complex T cell-mediated 
autoimmune response. Experimental autoimmune encephalomyelitis (EAE) is a TH 
cell-mediated demyelinating autoimmune disease of the central nervous system (CNS) 
and serves as the animal model for multiple sclerosis. We have recently shown that 
aly/aly mice are susceptible to EAE induced by adoptive transfer of MOG35-55-specific 
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T cells, indicating that the migration of fully primed pathogenic T cells to SLTs is not 
a prerequisite event prior to their invasion of the CNS 18. To assess the role of SLTs in 
T cell priming, we induced EAE in aly/aly or aly/+ mice by active s.c. immunization 
with MOG35-55 emulsified in CFA. Fig. 1d shows that aly/aly mice are completely 
resistant to EAE, compared to aly/+ control mice indicating that pathogenic T cells 
cannot be raised in aly/aly mice. To verify this notion, aly/aly and aly/+ mice were 
immunized s.c. with MOG35-55. 11 dpi, splenocytes were harvested, MOG35-55-reactive 
cells were expanded in vitro and subsequently transferred into aly/aly as well as aly/+ 
recipients. Fig. 1e shows that only cells derived from aly/+ donors were able to 
induce disease regardless whether the recipients had SLTs (aly/+) or not (aly/aly). 
However, MOG-reactive T cells derived from aly/aly donors were not pathogenic and 
did not mediate CNS-inflammation.  
 
Autoimmune disease develops in the absence of SLTs after s.c. immunization 
with auto-Ag 
The fact that aly/aly mice do not develop autoimmune disease could be explained by 
their inability to prime self-reactive T cells i) due to the lack of LNs as suggested by 
others 12, 19, or ii) by a direct impact of the NIK mutation on immune cells 20, 21. In 
order to define whether the developmental malformation in aly/aly mice is responsible 
for their resistance to develop EAE, we generated a series of bone marrow (BM)-
chimeric mice. To restrict the NIK mutation to the hematopoietic system, lethally 
irradiated aly/+ mice were injected with BM stem cells from aly/aly donor mice 
(aly/aly?aly/+). Conversely, to conserve the developmental structural defects, 
without the NIK-lesion of the hematopoietic compartment, aly/aly mice were 
reconstituted with BM-cells of normal aly/+ donors (aly/+?aly/aly). Spontaneous 
development of lymphoid tissues in aly/aly recipients upon reconstitution was 
expectedly not detected. Surprisingly, we discovered that aly/+?aly/aly BM-
chimeras were fully susceptible to EAE after s.c. immunization with MOG35-55 (Fig. 
2a), clearly demonstrating that s.c. immunization can mount a productive T cell-
driven autoimmune response even in the absence of draining LNs. Using the 
reciprocal approach, by generating aly/+?aly/+ (NIK+/+ immune system and normal 
SLTs) as well as aly/aly?aly/+ BM-chimeras (NIK-deficient immune system and 
normal SLTs), we found that the NIK mutation lead to EAE resistance even when the 
lymphoreticular compartment is unperturbed (Fig. 2b). In support of this, we found 
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that unmanipulated LTβR-/- mice, which also lack all LNs but have normal NIK 
function, are also fully susceptible to EAE (Supplementary Fig. 1a). 
The formation of IFNγ and IL-17 secreting auto-reactive T cells has been 
demonstrated to be a prerequisite for the development of autoimmunity 22. To 
specifically measure the impact of NIK on the development of Th-17 cells, LNs of 
MOG-immunized aly/+?aly/+ and aly/aly?aly/+ BM-chimeras were analyzed for 
IL-17 and IFN-γ production by enzyme-linked immunospot analysis (Elispot). 
Aly/aly?aly/+ mice display a substantial reduction in IL-17 and IFN-γ producing 
cells compared to the control mice aly/+?aly/+ (Fig. 2c) indicating that the resistance 
to EAE in the absence of NIK is due to the reduced generation of auto-reactive IFNγ 
and IL-17 secreting cells. Thus, the loss of NIK function impairs the capacity of 
aly/aly mice to generate pathogenic Th cells regardless of their structural defects. 
Our findings raise the issue that the immunodeficiency of aly/aly mice is disconnected 
from their structural malformations and due to the impact of NIK-signaling on 
immunity. Given the dogma that immunization-induced adaptive immunity requires 
the presence of SLTs, it is feasible that the spleen in aly/+?aly/aly BM-chimeras 
compensates for the absence of LNs and serves as an alternative site for T cell 
priming. In order to test this notion, we splenectomized aly/+?aly/aly BM-chimeras 
(aly/+?aly/alyspl) 14 days prior to the induction of EAE. Upon immunization with 
MOG, aly/+?aly/alyspl mice developed EAE with the same disease severity as 
control mice (Table 1). We noted a slight delay in disease onset when all SLTs are 
absent. Histology of CNS tissue however revealed no significant difference between 
aly/+?aly/+ and aly/+?aly/alyspl mice (Supplementary Fig. 1b). These data 
conclusively reveal that potent cellular immunity can be induced successfully upon 
s.c. immunization with Ag in CFA even in the absence of SLTs.  
 
Ab and GC formation is dependent on the structural support of SLTs 
The development of B cell activation and IgG class switching is generally held to 
require dedicated lymphoreticular structures and GC formation. Aly/aly mice are 
known for their inability to form GCs and intrinsic B cell defects, associated with the 
mutation in NIK, lead to impaired Ab responses and class switching 7. Again, to 
separate the structural malformations and the NIK lesion of the hematopoietic system, 
we found that anti-MOG Abs are virtually absent in mice without LNs (either 
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aly/+?aly/aly or aly/+?aly/alyspl). Yet, control mice (aly/+?aly/+ and 
aly/+?aly/+spl) elicit high anti-MOG Ab titers (Fig. 2d). Analysis of isotype subtypes 
revealed that in splenectomized alymphoplastic mice, anti-MOG IgM could be 
detected, while class switching to IgG did not occur (Fig. 2e-f). Anti-MOG IgA levels 
were low in all groups (Fig. 2g). Taken together, for B cell activation, the generation 
of high-affinity Igs and class switching, highly organized SLTs are obligatory.  
 
S.c. delivered Ag is transported into the liver in the absence of SLTs 
Since the loss of SLTs does not hinder the development of T cell immunity, we 
wanted to determine at which alternative site T cell priming could take place and to 
which organ the Ag travels from the site of immunization (s.c.). Therefore aly BM-
chimeras were injected s.c. with FITC-Dextran-coupled microspheres emulsified in 
CFA. 7dpi various organs (BM, thymus, CNS, liver, lung, blood, gut and in control 
mice spleen and LNs) were isolated and analyzed for the presence of fluorescent cells 
by flow cytometry. Fig. 3a shows that in control mice (aly/+?aly/+) FITC positive 
APCs were exclusively detected in LNs upon s.c. immunization. However, in 
aly/+?aly/alyspl BM-chimeras lacking SLTs, APCs carrying FITC beads migrate 
primarily to the liver and not the other organs analyzed. Interestingly, we further 
observed that upon s.c. immunization we reproducibly obtained a significantly greater 
number of mononuclear cells from the livers of aly/+?aly/alyspl mice when compared 
to aly/+?aly/+ or naïve mice (Fig. 3b).  
In order to determine whether lymphoid-like structures can be found in the liver, we 
analyzed the liver of MOG-immunized mice by histology (d7). We found that livers 
of aly/+?aly/alyspl BM-chimeras were severely inflamed in comparison to 
aly/+?aly/+ control mice (Fig. 4a-c). Detailed histological analysis displays dendritic 
cells (DCs) in close proximity to T cells in the infiltrated areas of the liver (Fig. 4c). 
Few FDCs, PNA+ cells and HEVs (CD62LL) were detected, which is in contrast to 
the described structured neogenesis of tertiary lymphoid structures. In the liver, we 
could also detect the accumulation of Ag-specific TcR Tg T cells (Supplementary Fig. 
2). 
Induced destruction of lymphoid structures inhibits B cell, but not T cell activity 
While SLTs require the presence of a cellular Anlage to form LNs and follicular 
structures, tertiary lymphoid development can be induced by chronic inflammation in 
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solid tissues (for review see 23). To determine whether newly formed tertiary 
lymphoid tissues (TLTs) can serve to propagate T cell expansion, we treated mice 
with LTβR-Fc fusion protein, which has been shown to efficiently disrupt follicular 
structures in SLTs and prevents the formation of TLTs 24. In agreement with the 
report by Gommermann et al. 25,  Fig. 4d demonstrates that LTβR-Fc treated mice are 
fully susceptible to EAE and display a similar clinical score as control mice. The 
splenic architecture of diseased mice treated with LTβR-Fc displays that PNA+ GC 
clusters are disrupted and FDCs are absent, verifying that LTβR-Fc fusion proteins 
completely prevented follicle formation (Fig. 4f). Anti-MOG Ab titers of diseased 
LTβR-Fc treated mice further revealed diminished levels of anti-MOG Abs (Fig. 4e 
and Supplementary Fig. 3). This however is not expected to impact on EAE in 
C57BL/6 mice, as they develop disease completely independent of B cells or anti-
MOG Abs, demonstrated by the susceptibility of B cell deficient mice to EAE 26, 27. 
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DISCUSSION 
A fundamental immunological dogma holds that primary adaptive immune responses 
are initiated in SLTs1. We wanted to investigate whether LNs are required for the 
development of T cell-mediated immunity induced by subcutaneous (s.c.) 
immunization. We found that aly/aly mice could mount a substantial DTH response 
after s.c. immunization with protein or peptide Ag. However, they are completely 
resistant to developing EAE induced by s.c. immunization with MOG35-55/CFA. Our 
results reveal that the lymphoreticular malformation is not the underlying cause of the 
immune-defects observed in aly/aly mice. The data presented here clearly demonstrate 
that mice lacking all SLTs are fully susceptible to EAE. Hence T cell priming and 
cellular immunity can be initiated in the absence of SLTs.  
We show that lesioning the function of NIK prevents the generation of pathogenic 
self-reactive TH17 cells and that it is the impaired NIK signalling in immune cells, 
rather than the absence of SLTs which prevents autoimmune disease from developing. 
In contrast to T cell priming, mice lacking SLTs (aly/+?aly/alyspl BMCs) or mice 
treated with LTβR-Fc, which disrupts lymphoreticular structures, are not capable to 
mount Ag-specific Abs and isotype switching. Thus, for B cell activation and the 
generation of high affinity Abs, the structural and functional support from dedicated 
SLTs is obligatory. 
Previously, Schirrmacher et al. suggested that the BM could be an alternative priming 
site for T cells28. They showed that blood-borne Ag can drive the expansion of 
adoptively transferred TcR Tg T cells independent of the presence of SLTs. Given 
that the priming requirements of a large population of adoptively transferred 
monoclonal TcR Tg T cells are likely less stringent than for endogenous naïve T cells, 
we extended this experiment to include the endogenous polyclonal Ag-specific 
population. Additionally, while blood-borne Ag, can reach virtually every tissue 
though the blood stream, we delivered an Ag depot s.c. and failed to observe any 
diffusion away from the injection site. In contrast, we found that the Ag is carried by 
local APCs from the site of immunization into the liver when SLTs are not available. 
In addition, we could demonstrate that s.c. immunization of mice lacking SLTs results 
in the accumulation of inflammatory T cells in the liver, suggesting that the liver can 
serve as a potential site of T cell priming when dedicated LNs are absent. While this 
immune function is not traditionally attributed to the adult liver, the fetal liver is a 
primary lymphoid organ hosting early hematopoiesis. We cannot claim that the liver 
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is the only potential site to host SLT-independent T cell priming, but our findings 
suggest that the adult liver has the potential to “remember” this function.  
Interestingly, during evolution, the appearance of adaptive immunity was brought 
about by the emergence of RAG in jawed fish 29-31. RAG mediates somatic 
recombination and is required for the formation of both B & T cell receptors, which 
appear to have emerged simultaneously during evolution. However, while the 
adaptive immune system is well developed in the oldest jawed vertebrates 
(cartilaginous fish e.g. sharks), Ig-class switching and GC formation are lacking. 
Class-switching only appeared at the time of the divergence of amphibians 32. The fact 
that cell-mediated immunity evolved earlier than modern humoral immune responses 
corroborates our discovery that T cell-mediated immunity can function outside of 
dedicated lymphoreticular structures. In summary, we found that B cells are 
dependent on the topography of dedicated lymphoid tissues, while T lymphocytes 
retain the capacity to recognize Ag in a structure-independent fashion. This finding 
has obvious implications for our understanding of adaptive immunity and vaccination. 
As for the development of autoimmune diseases, our findings show that self-reactive 
T cells may not need to be primed in tissue-draining LNs, but could occur at the 
inflammatory site or even in organs distant to the target tissue. 
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Table 1 Mice devoid of SLTs are fully susceptible to EAE. 
   
 
* of diseased animals 
 
BM-chimeras Incidence (%) Mean day of disease onset* 
Mean maximal 
clinical score* 
aly/+    ? aly/+ 94.7 (18 of 19) 11.4 3.0 
aly/+    ? aly/+spl 81.8 (9 of 11) 11.7 3.0 
aly/+    ? aly/aly 73.7 (14 of 19) 13.5 3.3 
aly/+    ? aly/alyspl 64.7  (11 of 17) 15.7 3.4 
aly/aly ? aly/+ 0 (0 of 10) - - 
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FIGURE LEGENDS 
Figure 1 DTH responses can emerge in the absence of SLTs. (a) DTH responses were 
induced by s.c. immunization with KLH in aly/aly and aly/+ mice. 11dpi, the mice 
were challenged by intradermal KLH (black bars), or PBS (grey bars) injection into 
the ear. Swelling was measured 24h post challenge and shown is the increase of ear 
swelling over baseline of a representative of 3 independent experiments (n ≥2 /exp). 
(b) Sera was collected from KLH-immunized aly/aly (?) and aly/+ mice (?) mice on 
12 dpi and analyzed for the presence of total anti-KLH Abs by ELISA. Results are 
representative of 3 independent experiments (n ≥ 2 mice/group). (c) FACS analysis of 
splenocytes derived from aly/aly and aly/+ mice transferred with CFSE-labeled 2D2 
(Va3.2+) cells and immunized s.c. with MOG35-55. Results are representative of 2 
individual experiments (n ≥ 2 mice/group). (d) EAE was induced by active 
immunization with MOG35-55/CFA in aly/aly (?) and aly/+ mice (?). (e) EAE was 
induced by adoptive transfer of pathogenic T cells derived from aly/aly or aly/+ 
donors into aly/aly or aly/+ recipients. aly/+ into aly/+: ▲, aly/+ into aly/aly: ∆, 
aly/aly into aly/+: ●, aly/aly into aly/aly: ○. Shown is a representative of two 
individual experiments (n ≥ 5 mice/group).  
 
Figure 2 SLTs are crucial for Ab affinity maturation and isotype switching. (a,b) 
EAE progression in BM-chimeras immunized s.c. with MOG35-55. (a) aly/+?aly/+: 
▲, aly/+?aly/aly: ●. (b) aly/aly?aly/+: □, aly/+?aly/+: ▲. (c) LN-derived cells 
were obtained from aly/aly?aly/+ (black bars) and aly/+?aly/+ (grey bars) BM-
chimeras 21 dpi with MOG35-55/CFA and rechallenged in vitro with 50µg/ml MOG35-
55 peptide to reveal IFNγ and IL-17 secreting cells using Elispot. Shown is the average 
of 3 mice/group (± SEM). (d-g) Titers of anti-MOG Abs determined from sera of 
diseased BM-chimeras by ELISA. (d) Total anti-MOG Igs. (e) Anti-MOG IgG. (f) 
Anti-MOG IgM. (g) Anti-MOG IgA. aly/+?aly/+: ■, aly/+?aly/+spl: □, 
aly/+?aly/aly: ▲, aly/+?aly/alyspl: ∆. Shown is the average of 3 mice/group (± 
SEM). 
  
Figure 3 Ag-laden APCs migrate to the liver in the absence of SLTs.  (a) Aly BM-
chimeras were injected s.c. with FITC-coupled microspheres and various organs were 
analyzed by FACS for the presence of FITC+ APCs 7dpi.  Data represent one of 3 
individual experiments. (b) Mean number (± SEM) of mononuclear cells isolated 
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from the livers of MOG-immunized BM-chimeras and naïve wt mice. Statistical 
significance was assessed using an unpaired Student t-test. ns: not significant, p > 
0.05. 
 
Figure 4 Accumulation of MOG-reactive T cells occurs in the liver in mice lacking 
SLTs.  (a,b) Liver cryosections from aly BM-chimeras immunized s.c. with MOG35-55 
(d7) were stained with H&E.  Bar: 500 µm. (c) Higher magnification image indicated 
by the region square in (B) stained with H&E and mAbs against CD3 and CD11c. 
Bar: 100 µm. (d) EAE was induced by s.c. immunization with MOG33-55 in LTβR-Fc 
treated (▲) and untreated (□) wt mice. Results are representative of 2 independent 
experiments (n ≥ 5 mice/group). (e) Total anti-MOG Ab ELISA from sera of diseased 
LTβR-Fc (▲) and untreated wt mice (□). Shown is the average of 4 mice per group ± 
SEM. (f) Cryosections of spleen obtained from immunized LTβR-Fc treated and 
untreated wt mice stained with PNA. Bar: 200 µm. 
 
Supplementary Figure 1 (a) EAE was induced in LTβR-/- mice and disease 
development was assessed as described. LTβR-/- (∆) mice are fully EAE susceptible 
when compared to C57BL/6 (■) wt mice (n=6). 
(b) H&E stainings of spinal cord sections of diseased aly/+?aly/+ and 
aly/+?aly/alyspl BM-chimeras. Lower row represents higher magnification of the 
insert in upper row. Bar in upper row: 200 µm and in lower row: 50 µm. 
 
Supplementary Figure 2 (a) aly/+?aly/+ and aly/+?aly/alyspl BM-chimeras were 
injected with 20x106 CFSE-labeled splenocytes from SMARTA/Thy1.1 TcR 
transgenic mice and immunized s.c. with p11 peptide of LCMV gp61 emulsified in 
CFA. 5 dpi LNs (only in aly/+?aly/+) and liver-invading cells were analyzed by 
flow cytometry by gating on Thy1.1+ cells (n = 3 mice/group). (b) 4 dpi with p11, 
liver sections were stained with αThy1.1 to reveal Ag-driven T cells accumulating in 
the livers of aly/+?aly/alyspl mice. Scale bar: 500 µm. 
 
Supplementary Figure 3 Anti-MOG Ab ELISA from sera of diseased LTβR-Fc 
treated (▲) and untreated (□) mice (d17). (a) Anti-MOG IgG. (b) Anti-MOG IgM. (c) 
Anti-MOG IgA. Shown is the average of 4 mice per group (± SEM). 
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MATERIAL AND METHODS 
Mice. C57BL/6 mice were purchased from Harlan Laboratories. Alymphoplasia 
(aly/aly) mice were bred in house under SPF-conditions. Heterozygous aly (aly/+) 
mice were used as controls for homozygous aly mice (aly/aly). 2D2 (MOG-TCR Tg) 
were provided by V. Kuchroo (Harvard Medical School, Boston, Massachusetts), 
SMARTA mice (carrying an MHC II restricted TcR specific for gp61 of LCMV) were 
obtained from R. Zinkernagel (University Hospital Zurich, Zurich, Switzerland), 
LTβR-/- mice were provided by A. Aguzzi and M.Heikenwalder (University Hospital 
Zurich, Zurich, Switzerland) and OTII mice were purchased at Jackson Laboratories. 
All mice were bred in house under SPF-conditions. BM-chimeras were generated as 
described previously 33, 34. Mice were splenectomized as described previously 18. 
Animal experiments were approved by the Swiss veterinary Office (68/2003, 70/2003 
and 13/2006).  
LTβR-Fc treatment. C57BL/6 mice were injected i.p. with 100 µg of human LTβR-
Fc Fusion protein (generously provided by Dr. Yang Xin Fu, University of Chicago) 
or 100 µg human IgG control (Bioexpress) 7 days prior to immunization with MOG 
and weekly thereafter.  
Induction of EAE. MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was 
obtained from GenScript. EAE was induced as described previously 35 with the 
modification that BM-chimeras were generally not boosted with pertussis toxin. For 
adoptive transfer MOG-reactive lymphocytes were generated as described 33. Each 
time point shown is the average disease score of each group ± SEM. 
Delayed-type hypersensitivity (DTH) assay. Mice were immunized s.c. with 100 
µg/flank of MOG35-55 peptide , or KLH (Sigma) emulsified in CFA. 11dpi, mice were 
challenged by injecting 10 µg/10µl of MOG35-55 peptide, KLH, PBS into the dorsal 
surface of the ear. DTH responses were determined by measuring the ear thickness 
using a calliper micrometer (Mitutoyo) 24 h after challenge and ∆ ear swelling was 
established by the increase in ear thickness over baseline (pre-challenge ear 
thickness).  
Lymphocyte isolation. Mice were euthanized with CO2 and various organs were 
removed to isolate lymphocytes: Spleen, LNs, thymus and lung were homogenized 
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and bone marrow cells were isolated by flushing the bones with PBS. The cells were 
strained through a 100 µm nylon filter (Fisher) and washed. Blood, BM and splenic 
red blood cells were lysed. For isolating hepatic non-parenchymal cells, the liver was 
incubated with DNase (0.5mg) / Liberase (1mg/ml) (Roche) for 30 min at 37°, 
homogenized and centrifuged at RT for 2 min. The supernatant was then centrifuged 
at 1500 rpm for 10 min and the pellet was resuspended in 30% Percoll (Pharmacia) 
and centrifuged at 12000 rpm for 30 min at 4C°. The interphase cells were collected 
and washed. For isolating intestinal lymphocytes, intestines were opened 
longitudinally, washed and cut into small pieces. Tissues were then incubated with 
DNase/Liberase and lymphocytes were isolated using a percoll gradient as described 
above. Isolation of CNS lymphocytes has been described previously 33, 35.  
Proliferation assay. Mice were injected with 20x106 CFSE (carbofluorescein 
diacetate succinimidyl ester)-labeled (Invitrogen-Molecular Probes) (10µM) 2D2 
splenocytes and immunized s.c. with 200 µg of MOG35-55 emulsified in CFA. 4 dpi, 
mice were sacrificed and spleens were analysed by FACS for the proliferation of 
CD4+ T cells using the 2D2 specific TCR Va3.2 antibody. 
Histology and flow cytometry. Tissues were freshly snap-frozen in liquid nitrogen. 
To determine infiltration of inflammatory cells, tissue sections were stained with 
hematoxylin and eosin (H&E) or with the following mouse-specific antibodies (Abs) 
as previously described 18: anti-CD11c (Jackson ImmunoResearch Labs) and anti-
CD3 (BD-Pharmingen). GCs cells were stained with peanut agglutinin (PNA; Vector 
Laboratories). 
For FACS analysis the following Abs were used: anti-CD11c, anti-CD11b, anti-
Va3.2, anti-Thy1.1 (BD). The cells were analyzed using a FACS-Canto (BD) with 
Cell-DivaTM software. Post-acquisition analysis was performed using FLOWJOTM 
software. To trace the distribution of Ag after immunization, mice were injected s.c. 
with 200 µl FluoresbriteTM Carboxylate YG 1.0 micron microspheres (Polysciences) 
emulsified in CFA supplemented with 5 mg/ml of Mycobacterium tuberculosis. 7 
days after injection mice were euthanized with CO2 and organs removed to isolate 
lymphocytes as described above.  Single cell suspensions were analyzed by FACS for 
the presence of FITC+ cells. 
46 
Enzyme-linked immunosorbent assay (ELISA). Plates were coated with 10µg 
rMOG1-121 or KLH in 0.1 M NaHCO3 (pH 9.6) at 4°C overnight and blocked with 1% 
(w/v) bovine serum albumin (BSA). Diluted sera were incubated for 2h at RT. After 
washing, peroxidase-conjugated antibodies to mouse Ig’s, IgG, IgA, IgM (Sigma) 
were added (1:1000 diluted) and incubated for 1h at RT. Plates were washed and 
chromogen (Biosource) was added. Absorbance was measured on a micro plate reader 
(450nm) (Bio-Rad). 
Enzyme-linked immunospot analysis (Elispot). 2 x 105 cells were plated in medium 
containing 10% FCS and MOG35-55 50µg/ml in 96 well  plates (Millipore) coated with 
the capture Ab against either IFNγ or IL-17A35. Elispots were revealed as described 
previously35 and subsequently analyzed on an Elispot reader (CTL immunospot). 
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Experimental autoimmune encephalomyelitis repressed by 
microglial paralysis
Frank L Heppner1, Melanie Greter1,2, Denis Marino1, Jeppe Falsig1, Gennadij Raivich3, Nadine Hövelmeyer4, 
Ari Waisman4, Thomas Rülicke5, Marco Prinz1,7, Josef Priller6, Burkhard Becher2 & Adriano Aguzzi1
Although microglial activation occurs in inflammatory, degenerative and neoplastic central nervous system (CNS) disorders, its 
role in pathogenesis is unclear. We studied this question by generating CD11b-HSVTK transgenic mice, which express herpes 
simplex thymidine kinase in macrophages and microglia. Ganciclovir treatment of organotypic brain slice cultures derived from 
CD11b-HSVTK mice abolished microglial release of nitrite, proinflammatory cytokines and chemokines. Systemic ganciclovir 
administration to CD11b-HSVTK mice elicited hematopoietic toxicity, which was prevented by transfer of wild-type bone marrow. 
In bone marrow chimeras, ganciclovir blocked microglial activation in the facial nucleus upon axotomy and repressed the 
development of experimental autoimmune encephalomyelitis. We conclude that microglial paralysis inhibits the development 
and maintenance of inflammatory CNS lesions. The microglial compartment thus provides a potential therapeutic target in 
inflammatory CNS disorders. These results validate CD11b-HSVTK mice as a tool to study the impact of microglial activation on 
CNS diseases in vivo.
Microglial cells are of hematopoietic origin and populate the CNS 
early during development to form a regularly spaced network of ram-
ified cells1. Microglia become rapidly activated in most pathologi-
cal  conditions of the CNS. Although microglial activation has been 
described extensively in many CNS diseases1, its impact on disease 
pathogenesis remains ill defined1,2. In autoimmune diseases such as 
multiple sclerosis, most data point to a detrimental role of microglia, 
for example by producing neurotoxic molecules, proinflammatory 
cytokines, chemokines or by presenting self-antigens3–6. But there have 
been claims that microglial activation in other diseases may counteract 
the pathogenic changes by providing neurotrophic or immunosup-
pressive factors7,8.
We wished to investigate the role of activated microglia using a 
 pharmacogenetically inducible in vivo model of microglial paralysis. We 
have therefore generated transgenic mice in which the thymidine kinase 
of herpes simplex virus (encoded by HSVTK) is driven by the CD11b 
promoter9. CD11b, encoded by Itgam, is the alpha chain of the Mac-1 
integrin and is expressed in cells of myeloid origin, including macro-
phages and microglia. We used a 1.7-kilobase CD11b promoter fragment 
which drives sustained expression in macrophages of transgenic mice 
at levels similar to those of the endogenous CD11b gene9. HSVTK is a 
suicide gene that converts antiviral nucleotide analog  prodrugs such 
as ganciclovir (GCV) to a monophosphorylated form, which is then 
transformed into a toxic triphosphate by endogenous  cellular kinases10. 
Expression of HSVTK renders preferentially  proliferating cells sensi-
tive to GCV, as the active metabolite competes with thymine for DNA 
synthesis. This strategy has been used to  selectively ablate defined cell 
lineages, for example in transgenic mice11,12.
Nondividing HSVTK+ cells also show susceptibility to GCV, albeit 
at reduced levels: in this case, toxicity has been ascribed to interference 
with mitochondrial DNA synthesis13. Here we report that microglial 
cells of CD11b-HSVTK transgenic mice, although mostly resting in the 
adult CNS, are efficiently paralyzed by GCV administration. We took 
advantage of this phenomenon to study the contribution of micro-
glial activation to two disease models: facial nerve transection and 
 experimental autoimmune encephalitis.
RESULTS
Characterization of transgenic mice
Before generating transgenic mice, the CD11b-HSVTK transgene was 
stably transfected into the BV-2 microglial cell line, and GCV was 
added to the culture medium. We detected efficient, dose-dependent 
killing of microglial cells with a significant difference between BV2-
TK and controls at 2, 10 and 20 µm GCV (P < 0.001, one-way ANOVA 
test), confirming the functionality of the suicide approach (Fig. 1a). 
We then established two independent transgenic mouse lines denoted 
B6,D2-Tg(CD11b-HSVTK)618Zbz (tg618) and B6,D2-Tg (CD11b-
HSVTK)620Zbz (tg620), and confirmed integration of the transgene by 
1Institute of Neuropathology, University Hospital Zurich, CH-8091 Zurich, Switzerland. 2Department Neurology, Neuroimmunology Unit, University Hospital Zurich, 
CH-8091 Zurich, Switzerland. 3Perinatal Brain Repair Group, Department of Obstetrics and Gynaecology and Department of Anatomy, University College London, 
WC1E 6HX London, UK. 4Laboratory for Molecular Immunology, Institute for Genetics, University of Cologne, D-50931 Cologne, Germany. 5Institute of Laboratory 
Animal Science, University of Zurich, CH-8091 Zurich, Switzerland. 6Departments of Psychiatry and Experimental Neurology, Charité, Humboldt-University Berlin, 
10117 Berlin, Germany. 7Present address: Institute of Neuropathology, Georg-August-University Göttingen, D-37075 Göttingen, Germany. Correspondence should be 
addressed to A.A. (adriano@pathol.unizh.ch).
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Southern blotting and PCR of genomic DNA (Fig. 1b,c). In the absence 
of GCV, transgenic offspring showed no phenotypic alterations except 
for male sterility, which is a known consequence of ectopic HSVTK 
expression14. Line tg620 was backcrossed to C57BL/6 mice for nine 
generations and was used for all of the experiments described below.
Expression of HSVTK was ascertained by western blot analysis 
of various organs. As expected, all macrophage-containing organs, 
including spleen, lung and brain, showed sustained expression of the 
HSVTK transgene (Fig. 1d,e). Western blot analysis of purified micro-
glial and astroglial cells derived from CD11b-HSVTK mice established 
that transgene expression within the CNS was present in microglial 
cells but not in astrocytes (Fig. 1f). Addition of GCV to primary micro-
glial cell cultures (>98% purity, Fig. 1f), or to mixed glial cell cultures, 
led to lineage-specific death of microglial cells (Fig. 1g,h).
We then administered GCV to tg620 mice intraperitoneally or in 
drinking water. Circulating CD11b+ cells were substantially reduced 
after 3 d and almost entirely ablated after 5–6 d, whereas B- and T-cell 
counts were essentially unaltered (Fig. 2a). After 7 d of GCV treatment, 
tg620 mice developed fatal aplastic anemia with reduced erythroid and 
myeloid cell compartments in both bone marrow and peripheral blood 
(Supplementary Fig. 1 and Supplementary Table 1 online). Analysis 
of prenatal hematopoiesis in tg620 embryos at embryonic day 14.5 
showed GCV-mediated ablation of CD11b+ AA4.1+ hematopoietic 
precursor cells15 (Supplementary Fig. 1 online), which therefore seem 
to be crucial for normal hematopoietic development.
Microglia-restricted HSVTK expression in tg620chi mice
To restrict HSVTK expression to microglial cells and to overcome 
GCV-mediated myelotoxicity, we generated bone marrow chimeras. 
For donors, we used fetal liver cells (FLCs) or bone marrow derived 
from wild-type mice or congenic C57BL/6-β-actin-GFP mice16. 
Lethally irradiated tg620 transgenic mice were used as recipients. This 
strategy is based on the fact that monocytes and extraneural tissue 
macrophages are rapidly and efficiently repopulated upon adoptive 
bone marrow transfer, whereas recruitment of radioresistant microg-
lia from the peripheral hematopoietic pool to the CNS is slow and 
rather inefficient17–20. Chimeric tg620 mice hosting wild-type bone 
 marrow (termed tg620chi) showed stable numbers of peripheral 
CD11b+  monocytes and macrophages upon long-term GCV treatment 
(Fig. 2b). In reciprocal experiments, tg620 bone marrow was transferred 
to wild-type recipients. The latter mice experienced GCV-mediated loss 
of peripheral CD11b+ cells and aplastic anemia (Fig. 2b) similar to tg620 
mice. Intactness of the blood-brain barrier in both GCV-treated and 
untreated tg620chi mice was shown by the lack of increased IgG influx 
into the CNS21. This excluded the possibility of radiation-induced 
blood-brain barrier leakage (Supplementary Fig. 2 online).
Microglial paralysis after GCV treatment
To assess the efficiency and specificity of paralyzing microglia in 
tg620chi mice, we performed unilateral transections of the facial nerve. 
a
b
c
d
e
f
g
h
CD11b
Figure 1  Characterization of CD11b-HSVTK transgene and transgenic mice. 
(a) Cell viability assay of microglial BV-2 cell clones stably transfected with 
CD11b-HSVTK (BV2-TK; circles, inverted triangles and diamonds). 
CMV-GFP-transfected BV-2 (BV2-GFP; triangles) and untransfected 
BV-2 controls (BV2; squares) served as negative controls. Ordinate: mean 
and s.d. of cell numbers on day 6 divided by cell numbers on day 0. 
(b) CD11b-HSVTK transgene depicting the CD11b promoter, the HSVTK gene 
and the human growth hormone gene (hGH) providing splice donor/acceptor 
sites and a polyadenylation signal9. For the Southern blot (below), an 
HSVTK-specific 530-bp PCR probe (hatched box) was hybridized to a 
fragment of 1169 bp (arrow on the left) in transgene-positive tg618 
(lane 2: founder; lane 3: F1 offspring) and tg620 mice (lane 4: founder; 
lane 6 and 7: F1 offspring) and not in negative littermates (lanes 1,5). As 
positive control, 10-fold dilutions of CD11b-HSVTK plasmid were spiked in 
genomic DNA of wild-type mice (ranging from 1,125 pg (lane 8) to 1.125 pg 
(lane 11)). Larger bands in lanes 8 and 9 correspond to incompletely digested 
plasmid. Right, molecular weight in kb. (c) PCR of genomic DNA resulted in 
a transgene-specific band at 599 bp. (d) Western blot of brain tissue: HSVTK 
transgene is expressed in CD11b-HSVTK (lane 3) and GFAP-HSVTK brains12 
(lane 2, positive control). No signal in negative littermates (lanes 1, 4). Right, 
molecular weight in kDa. (e) Western blot of various organs: strong expression 
of HSVTK in testis14 (lane 1) and in macrophage-containing organs. Up to 
four HSVTK proteins were detectable due to cryptic translational initiation 
sites in the coding region of HSVTK46. (f) Western blot of isolectin IB4+–
microglial (upper right, green color; left, light microscopic (LM) image) and 
astrocyte cell culture lysates of tg620 mice shows HSVTK protein expression 
in microglial cells (lane 5), but not in astrocytes (lane 3). Tg620 spleen 
homogenate (lane 7) and stably CD11b-HSVTK-transfected microglial BV-2 
cells (lane 2), positive controls; microglia and astrocytes of non-transgenic 
littermates (lane 6 and 4) and GFP-transfected BV-2 cells (lane 1), negative 
controls. (g) Strong reduction of transgenic microglial cells in the presence 
(filled triangle), but not in the absence of GCV (filled squares), whereas wild-
type microglia in the presence (open squares) or absence (open circles) of 
GCV were stable. Number of microglia was normalized to 100% at day 0 and 
experiments were done in triplicates. (h) Whereas microglia (IB4+, green) 
were strongly reduced in mixed glial cell cultures derived from tg620 mice, 
GFAP+ astrocytes (red) appeared to be unaffected by GCV (lower left).
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Subsequent retrograde degeneration strongly 
activates  microglia within the respective facial 
motor nucleus22. Here, GCV  administration 
to tg620chi mice considerably repressed acti-
vation of microglia (Fig. 3a), most likely as 
a result of activation-induced  upregulation 
of CD11b-HSVTK which hypersensitizes 
microglia to GCV. No differences were seen 
in microglial activation within lesioned 
facial nuclei of non-GCV-treated tg620 mice 
or nontransgenic littermates in the presence 
or absence of GCV (data not shown). GCV-
mediated microglial paralysis of tg620chi mice 
for 7 weeks in the absence of a pathological 
stimulus did not result in obvious  phenotypic 
or  histopathological changes except for a 
decrease in microglial cell numbers as assessed 
by FACS analysis (Supplementary Fig. 3 
online). Although it is theoretically possible 
that ablation of microglia in nondiseased chi-
meric tg620 mice may result from radiation 
toxicity, we consider this unlikely, as others 
have found normal numbers of ramified, res-
ting microglia after irradiation at time points 
similar to the ones described here19.
We then assessed the functional consequen-
ces of microglial paralysis in organotypic hippocampal slice cultures 
(OHSCs). OHSCs  derived from tg620 mice were stimulated with lipo-
polysaccharide (LPS) and interferon (IFN)-γ, and microglial activation 
in the  presence or absence of GCV was determined. GCV treatment 
of stimulated OHSCs  inhibited microglial activation (Supplementary 
Fig. 4 online) and abrogated the release of nitrite, tumor necrosis factor 
(TNF) and macrophage inflammatory protein (MIP)-1β (Fig. 3b–d). 
These factors are thought to interfere with CNS homeostasis either 
by damaging tissue directly, or by attracting and/or activating other 
immune cells including autoreactive T cells in experimental autoim-
mune encephalitis (EAE)5.
Repression of EAE in bone marrow chimeric tg620 mice
Having established that GCV treatment of tg620chi mice resulted in 
profound paralysis of microglia within the CNS, we studied the impact 
of microglial paralysis on the pathogenesis of EAE.  Age-matched 
female tg620chi and wild-type mice were 
immunized with an encephalitogenic syn-
thetic myelin oligodendrocyte glycoprotein 
(MOG35–55) peptide. Untreated tg620
chi mice 
and wild-type mice reconstituted with wild-
a b
Figure 2  In vivo characterization of tg620 mice and FACS analysis of peripheral blood. (a) In tg620 
(tk+) mice, we observed a drastic GCV-mediated decrease of CD11b+ monocytes and granulocytes, 
whereas B220+ B cells and Thy1.2+ T cells were unaffected (right panels). GCV treatment of 
nontransgenic littermates (tk–), even at doses that were 10 times higher, did not elicit alterations in the 
blood leukocyte numbers (left panels). (b) In tg620chi mice, the GCV-mediated loss of CD11b+ cells 
was rescued upon adoptive transfer of wild-type bone marrow (tk– → tk+; middle panels). Tg620chi mice 
were indistinguishable from nontransgenic littermates receiving the same treatment (tk– → tk–; right 
panels). Adoptive transfer of tg620 bone marrow into wild-type mice (tk+ → tk–; left panels) restored 
susceptibility of CD11b+ cells to GCV. Thy1.2+ T cells and B220+ B cells were unaffected in all 
experimental groups. Numbers indicate percentage of cells. Arrows indicate transfer of bone marrow.
a
b c d
Overview Lesioned side Unlesioned side
Figure 3  Microglial paralysis in tg620 mice. 
(a) GCV-mediated microglial paralysis within the 
facial nucleus of tg620chi mice 7 d after axotomy 
of the left facial nerve. Strong activation and 
proliferation of CD11b+ microglial cells (brown) 
within the corresponding facial motor nucleus 
of GCV-treated bone marrow chimeric wild-type 
mice (tk– → tk–; upper left and middle) was 
seen versus complete inhibition of microglial 
activation within lesioned facial nuclei of 
GCV-treated tg620chi mice (tk– → tk+; lower left 
and middle). Activated (insert, upper middle 
panel) but not paralyzed microglia (insert, lower 
middle panel) was attached to cell bodies of 
injured neurons. n = 3–4 mice/group. Circles 
indicate the facial motor nuclei. Scale bars: left 
panel, 1 mm; middle and right panels, 100 µm. 
(b–d) GCV treatment abrogated the LPS-IFN-γ-
induced (black bars) release of microglial 
TNF (b), nitrite (c) and MIP-1β (d) in OHSCs from 
tg620 mice. White bars, nonstimulated OHSCs. 
Statistical significance was assessed by a one-
way ANOVA test. ∗∗∗P < 0.001.
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type bone marrow showed similar onset and severity of EAE (Fig. 4a), 
whereas GCV treatment of tg620chi mice resulted in a considerable 
delay in disease onset and in  repression of clinical EAE signs (Fig. 4b; 
P < 0.01–0.05, one-way ANOVA test including Bonferroni’s Multiple 
Comparison post test). Conversely, comparison of transgenic tg620 
mice with nontransgenic littermates (with or without GCV) showed 
indistinguishable clinical disease development (Supplementary Fig. 5 
online). GCV itself did not influence EAE, as the clinical course of bone 
marrow–reconstituted wild-type littermates of tg620 mice was identi-
cal to that of wild-type bone marrow–reconstituted mice  regardless of 
GCV treatment (Fig. 4a).
Notably, GCV administration did not alter the cellular  composition 
and function of the peripheral immune system of tg620chi mice. 
FACS analysis of peripheral blood showed no abnormalities 
in  relative  numbers of Thy1.2+ T cells, B220+ B cells, as well as 
CD11b+  monocytes and granulocytes (data not shown). GCV treat-
ment of tg620chi and control mice also did not alter the prolifera-
tive response of T cells from mice immunized with keyhole limpet 
 hemocyanin (KLH; data not shown) or MOG in in vitro recall assays 
(Fig. 4c and Supplementary Fig. 6 online). 
In addition, levels of IFN-γ and interleukin 
(IL)-2 were similar in GCV-treated versus 
untreated tg620chi mice after recall with KLH 
(data not shown) or MOG (P > 0.05, one-way 
ANOVA and Tukey post test), except for a diffe-
rence in IFN-γ production between nonchime-
ric and chimeric mice, which can be attributed 
to the reconstitution procedure (Fig. 4d). MOG 
recall assays allowed us to directly address 
the performance of  encephalitogenic T cells 
in response to their cognate antigen upon 
in vivo priming. The results suggest that 
T cells of GCV-treated  chimeric tg620 mice 
are fully capable of inducing expansion 
and effector function of MOG-reactive 
lymphocytes compared to their non-
GCV-treated counterparts (Fig. 4c,d and 
Supplementary Fig. 6 online). These experi-
ments validate that GCV treatment does not 
alter a number of critical immune functions of 
tg620chi mice, including the ability to mount 
an encephalitogenic immune response.
Histological examination showed that cli-
nical EAE signs  correlated with the extent of 
inflammatory CNS infiltrates (Fig. 5a–c). 
Immunohistochemical staining for Iba1, 
which identifies  monocytes, macrophages 
and microglia23, showed positive  infiltrates 
mainly within the spinal and cerebellar white 
matter (Fig. 5a,b). Accordingly, both myelin 
and axons seemed to be damaged (Fig. 5a). 
But, in line with the clinical performance, 
MOG-immunized tg620chi mice  treated with 
GCV showed few Iba1+ infiltrates and did not 
show major  myelin or axonal destruction 
(Fig. 5a). We detected very little activated 
Iba1+ microglia in the CNS of GCV-trea-
ted tg620chi mice, whereas all control mice 
showed strongly activated Iba1+ microglial 
cells (Fig. 5a,b). MOG-immunized bone 
marrow chimeric wild-type control ani-
mals, in the presence or absence of GCV, regularly showed strong 
inflammatory changes (data not shown) indistinguishable from non-
GCV-treated tg620chi mice.
We then quantified and characterized inflammatory white- matter 
infiltrates by FACS analysis of mononucleated cells derived from spinal 
cord and brain stem tissue 14 d after MOG immunization (i.e., at the 
peak of clinical signs). In line with the  histological findings, we found 
a high percentage of infiltrating cells in CNS tissues of non-GCV-trea-
ted tg620chi mice, which consisted of CD45high CD11b– lymphocytes 
as well as of CD45high CD11b+ myeloid cells. Further  analysis showed 
that approximately two-thirds of the CD45high CD11b– infiltrating 
lymphocytes were CD4+ cells, whereas only a minority consisted of 
CD8+ cells (Fig. 5c). GCV treatment of tg620chi mice substantially 
reduced inflammatory infiltrates:  lymphocytes were decreased from 
36% to 10%, whereas the amount of infiltrating CD45high CD11b+ 
monocytes was reduced by 40% (Fig. 5c). As expected, there were no 
obvious differences in the numbers of CD45intermediate CD11b+ micro-
glial cells in GCV-treated versus untreated tg620chi mice. Moreover, 
the numbers of GFP+  microglia recruited from the extraneural pool 
Figure 4  Microglial paralysis represses clinical EAE in tg620chi mice. (a,b) Clinical EAE score of 
bone marrow chimeric mice upon MOG immunization: all control mice showed severe EAE signs (a). 
GCV-treated bone marrow chimeric tg620chi mice showed considerably repressed EAE (open circles). 
Omission of GCV treatment of bone marrow chimeric tg620chi mice resulted in severe EAE (closed 
circles) (b). Controls consisted of congenic β-actin-GFP (wtGFP) bone marrow chimeric wild-type mice (tk–) 
treated (wtGFP → tk–/GCV, blue triangle) or not treated (wtGFP → tk–, yellow diamond) with GCV, tg620chi 
mice (wtGFP → tk+, black circle) and wild-type mice with transgenic tg620 bone marrow (tk+ → tk–, red 
diamond) and tg620 mice with transgenic tg620 bone marrow (tk+ → tk+, green square), the latter two 
in the absence of GCV. Arrows indicate bone marrow transfer. Experiments were repeated three times for 
bone marrow chimeric tg620 and wild-type mice with or without GCV and showed identical results. 
n = 9–13 mice/group. (c,d) GCV-treated tg620chi mice are fully capable of driving TH1 immunity. Recall 
proliferation (c) and IFN-γ secretion (d) of encephalitogenic T cells in response to MOG in the presence or 
absence of GCV. Experimental groups consisted of tg620chi (filled black squares and filled red triangles), 
wtchi (filled black triangles and filled black diamonds), wild-type (filled black circles and open squares) 
and tg620 mice (open triangles) treated with GCV or not, as depicted. Each symbol represents the mean 
for triplicate cultures; bars indicate the mean proliferation per experimental group. The proliferation index 
is calculated as fold increase in T-cell proliferation upon MOG recall compared to medium only. A detailed 
analysis of tg620chi T-cell proliferation upon MOG recall is shown in Supplementary Fig. 6 online.
a b
c d
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of macrophages in MOG-immunized mice were similar in the absence 
or presence of GCV (Supplementary Fig. 7 online).
DISCUSSION
The data described here indicate that GCV administration to tg620 
mice brings about efficient conditional paralysis of microglia in vivo. 
Treatment with GCV in vivo results in substantial inhibition of microg-
lial  activation upon facial axotomy, and abolishes the release of microg-
lia-derived nitrite and proinflammatory cytokines and chemokines 
from activated brain-slice cultures. In EAE, microglial paralysis results 
in substantial amelioration of the clinical signs and in strong reduction 
of CNS inflammation. As facial nerve transection causes no disruption 
of the blood-brain barrier22, we conclude that GCV diffuses adequately 
into the intact CNS.
Immunomodulatory compounds, including IFN-β, copolymer I and 
statins, can repress CNS autoimmune diseases including EAE24–26. But 
these drugs exert additional ill-defined effects on many immune cells, 
including T cells and peripheral monocytes. Inhibition of peripheral 
macrophages has been shown to prevent EAE27,28, whereas microglial 
activation is thought to be secondary to infiltration of lymphocytes2. 
Accordingly, the pathogenesis of EAE is widely held to be triggered exclu-
sively within the peripheral immune system2,29.
Whereas the importance of autoreactive CD4+ T cells in EAE has 
been extensively documented, particularly by their ability to initiate 
disease, the effector mechanism leading to inflammation and demye-
lination within the CNS is likely to be provided by other cell types 
such as infiltrating macrophages and resident microglia29. But as a 
result of the dearth of suitable animal models, a definitive dissection 
of potential effector cell types involved, namely infiltrating macropha-
ges and resident microglia, has proven difficult. Early studies pointing 
to a more direct role of CNS-derived cells in the pathogenesis of EAE 
included the repression of EAE in bone marrow chimeric mice lacking 
CD40 or IL-23 predominantly in the CNS30,31. But these studies did 
not exclude other CNS residents than microglia as a potential source 
of these immunomodulators.
What are the mechanisms of microglia-mediated damage in EAE? 
Nitric oxide and its adducts may disrupt CNS tissue integrity26,32, 
whereas microglia-derived cytokines and chemokines such as TNF 
and MIP-1β activate and attract blood-derived leukocytes. These may 
in turn interfere with CNS homeostasis (e.g., by damaging myelin)5,26. 
Reactivation of myelin-specific T cells within the CNS upon recogni-
tion of local autoantigens is critical to induce and/or sustain EAE33. 
But it is still debated whether microglia present myelin-associated 
antigens to autoreactive T cells in vivo: it has been reported that the 
antigen-presenting capacity of CD45intermediate CD11b+ microglia is 
not essential for promoting encephalitogenic myelin-specific CD4+ 
T cells in vitro34, whereas others regard microglial presentation of 
myelin-associated antigens as critical6,35. Our data clearly establish 
a
b c
Figure 5  Microglial paralysis represses 
EAE-associated inflammatory infiltrates in 
tg620chi mice. (a) Spinal cords of MOG-
immunized and control mice (H&E, hematoxylin 
and eosin). Inflammation was largely confined 
to the white matter, leading to destruction of 
myelin tracts (LN, Luxol-Nissl stain) as well 
as axonal integrity (NF, neurofilament). No 
inflammation was seen in tg620 mice in the 
absence of MOG immunization (upper panel). 
Scale bar, 200 µm except for left column, 
500 µm. (b) Cerebella of MOG-immunized mice: 
tg620chi mice (wtGFP → tk+) in the absence of 
GCV (second panel from top) or of wtGFP bone 
marrow chimeric wild-type animals (wtGFP → tk–) 
treated with GCV (lower panel) or not (data not 
shown) showed severe inflammation mainly 
confined to the white matter. But tg620chi mice 
treated with GCV (third panel from top) showed 
neither activated Iba1+ microglia nor infiltrating 
leucocytes. No inflammation in tg620 mice 
in the absence of MOG-immunization (upper 
panel). Scale bar, 500 µm. (c) FACS analysis 
of spinal cord and brain tissue 14 d after MOG 
immunization. Whereas non-MOG-immunized 
tg620chi mice without (upper row) or with GCV 
(data not shown) showed few CD45high CD11b– 
lymphocytes in the CNS, MOG immunization 
induced a strong inflammatory infiltration 
in tg620chi mice in the absence of GCV 
(middle row) consisting of CD45high CD11b– 
lymphocytes and CD45high CD11b+ monocytes. 
GCV-mediated microglial paralysis resulted in a 
substantial reduction in inflammatory infiltrates 
in tg620chi mice (lower row). Infiltrating 
CD45high CD11b– lymphocytes consisted mainly 
of CD4+ T cells and few CD8+ T cells (middle 
and right). Numbers indicate percentages of 
cells. Each experimental group consisted of 
pooled homogenate derived from three mice 
representing the average clinical EAE score.
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that microglia are crucial for the development of EAE, which seems 
to be conferred by the release of cytokines and chemokines as well 
as reactive oxygen species. This view is in agreement with previous 
reports showing that chemokine secretion by CNS residents in vivo 
is vital for disease development30.
Even in the late neurodegenerative phase of EAE, which goes along 
with destruction of neurons, activated microglia may have a crucial 
role. Recent reports suggest an inverse relationship between microglial 
activation and neurogenesis36–38. One might therefore speculate that 
reduced neurogenesis, by decreasing the capacity for neural recovery, 
may exacerbate EAE.
From a translational viewpoint, the results reported here suggest 
that microglial activation may represent a target in the therapy of 
multiple sclerosis and other immune-mediated CNS diseases. In 
 addition to providing insights into the pathogenesis of autoimmune 
CNS diseases, tg620 mice are proving a useful tool for the study of 
microglial involvement in a broad variety of neuroimmune and 
neurodegenerative diseases, including encephalitides, Alzheimer, 
Parkinson, prion and motor neuron diseases.
METHODS
Transgenic mice. A 544-base pair BamHI fragment containing the Thy1 cDNA 
in pB203 derived from the CD11b-Thy1-human growth hormone (GH) cDNA9 
(provided by D.G. Tenen) was replaced by the BglII to BamHI HSVTK frag-
ment39. Correct construction of the transgene was confirmed by sequenc-
ing and by assessing GCV-mediated cell death of BV-2 microglial cells stably 
transfected with CD11b-HSVTK using electroporation in accordance with 
standard protocols. Following NotI and HindIII excision, we introduced 
CD11b-HSVTK into fertilized B6D2F2 hybrid eggs by pronuclear microin-
jection. We analyzed genomic integration by Southern blotting of SmaI-
digested genomic DNA according to standard procedures. An HSVTK-specific 
530-bp PCR probe was generated and labeled with α32P dCTP. The following 
primers were used (Microsynth): 5´-ACAATGGGCATGCCTTATGC-3´ and 
5´-GGACATATTGCACAAACGGA-3´. For routine genotyping, we performed 
PCR analysis on tail DNA in line with standard protocols using the follow-
ing primers (Microsynth): 5´-GACTTCCGTGGCTTCTTGCTGC-3´ and 
5´-GTGCTGGCATTACAGGCGTGAG-3´.
Bone marrow chimeric mice and GCV administration. We generated bone 
marrow chimeric mice as described30 with bone marrow of adult mice or FLCs, 
embryonic day 13.5–14.5. Recipient mice were lethally irradiated with 950 rad 
and injected intravenously either with 2 × 107 bone marrow cells or 1 × 107 
FLCs. Engraftment took place over 6–8 weeks. We defined successful reconsti-
tution as >95% engraftment of blood leukocytes by FACS analysis. Congenic 
C57BL/6 β-actin-GFP donor mice16 (Jackson Laboratories) were bred in house 
under pathogen-free conditions. We achieved GCV administration by intra-
peritoneal injection of 100 µg GCV (Cymevene; Roche) per gram of body mass 
every 2 d or orally by adding 60 µg/ml GCV to the drinking water.
Western blot analysis. We prepared 10% (wt/vol) homogenates of various 
organs or cell cultures according to standard procedures40. We used a polyclonal 
rabbit serum to HSVTK41 (1:5,000; provided by W.C. Summers) followed by 
incubation with a rabbit IgG-HRP-specific antibody (1:2,500; Zymed). Equal 
loading of protein (50 µg/lane) was assured by a bicinchoninic acid (BCA) assay 
according to standard procedures.
Cell cultures. Cultures of purified microglia and astrocytes were prepared and 
maintained as described42,43 in the presence or absence of 2.5 µg/ml GCV. 
Four high-power fields of three wells were counted on days 0, 3 and 6 using an 
inverted microscope (Zeiss). We identified microglia by fluorescein isothio-
cyanate–labeled Isolectin-B4 (1:50; Sigma); astrocytes were stained with an 
antibody to glial fibrillary acidic protein (1:300; Dako) and visualized by an 
Alexa 546-labeled secondary rabbit IgG-specific antibody (1:300; Juro). We per-
formed fluorescence microscopy on a Zeiss microscope (Axioplan 2) equipped 
with a digital camera (Axiocam).
Organotypic hippocampal slice cultures. OHSCs were prepared from 
12-d-old mice as described44, and, where indicated, treated with 5 µg/ml GCV 
from day 0 for the duration of the experiment. After 7 d, we initiated  activation 
of microglia by adding IFN-γ (10 ng/ml) and LPS (1 µg/ml). To assess nitric 
oxide adducts, cytokines and chemokines, cell culture supernatant was har-
vested 48 h after LPS and IFN-γ stimulation except for TNF measurements, 
for which supernatant was taken after 8 h. Each group contained 3–4 inserts 
with 4 OHSCs on each insert.
Induction and evaluation of EAE. We subjected 13–16-week-old 
mice to subcutaneous administration of 200 µg of MOG35–55 peptide 
(MEVGWYRSPFSRVVHLYRNGK; Neosystem) emulsified in complete Freund 
adjuvant supplemented with 4 mg/ml Mycobacterium tuberculosis (DIFCO), 
as described30. Mice received intraperitoneal injections with 200 ng pertussis 
toxin (Sigma) at the time of immunization and 48 h later. GCV administra-
tion started 7 d before MOG immunization. Mice were scored as described31. 
Animal experiments were approved by the Swiss Veterinary Office (#203/98, 
40/2002, 85/2003 and 136/2004).
Histology. Whole mouse brains or spinal columns were fixed in 4% paraformal-
dehyde in phosphate-buffered saline and embedded in paraffin or snap-frozen 
in liquid nitrogen. Antibodies to glial fibrillary acidic protein (1:300; Dako), 
synaptophysin (1:50; Zymed), microtubule-associated protein-2 (1:1,000; 
Sigma), neurofilament protein (200-kDa subunits; 1:20; Bio-Science) and Iba1 
(1:100; Wako Chemicals) were used. We used CD11b-specific antibodies (MCA 
711, 1:1,000; Serotec) only on cryosections.
Flow cytometry. We removed spinal cords and processed them for 
FACS analysis as described30,31. Peripheral blood or spleen and FLC sus-
pensions were analyzed according to standard protocols40. Fluorescein 
isothiocyanate–, phycoerythrin- or peridinin chlorophyll-a protein–
conjugated monoclonal antibodies to mouse CD11b, B220, CD8, CD4, Thy1.2, 
AA4.1, CD45 or biotinylated CD8- or CD11c-specific antibodies were used, 
the latter two coupled to a secondary streptavidin-labeled allophycocyanin 
antibody (Becton Dickinson). Data were acquired on a FACScalibur 
(Becton Dickinson).
Recall responses. Mice were primed by flank injections of 200 µg KLH (Sigma) 
or 200 µg MOG35–55 peptide (Neosystem) emulsified in complete Freund 
adjuvant. Mice received intraperitoneal injections of 200 ng pertussis toxin 
(Sigma) at the time of immunization. After 7 d, the axillary and inguinal lymph 
nodes were removed and homogenized. We placed 2 × 105 lymph node cells 
as triplicates in a 96-well plate and pulsed them with 100 µg KLH or MOG 
or 10 µg ConA (Sigma). After 24 h, cells were pulsed with 3[H]-thymidine 
(NEN-DuPont; final concentration 5 µCi/ml) and incubated for an additional 
24 h before they were harvested and thymidine incorporation was assessed 
using a Filtermate harvester (Packard Meriden) and TopCount-NXT Packard 
Microplate scintillation and luminescence counter. Supernatants of sister cul-
tures were harvested after 48 h and analyzed by ELISA.
Enzyme-linked immunosorbent assay (ELISA) and nitrite measurement. 
Supernatants derived from recall assays or OHSCs were analyzed by the use 
of ELISA kits for TNF, IFN-γ, IL-2 (Pharmingen) or MIP-1β (R&D systems) 
according to the manufacturer’s instructions. Nitrite was measured with the 
Griess reagent. We mixed 50 µl supernatant or NaNO2 standards with 25 µl 
N-(1-naphthyl)ethylenediamine (0.1% in water) and 25 µl sulfanilamide (1% 
in 1.2 N HCl) in a 96-well plate and the optical density was assessed after 3 min 
at 570–690 nm. To include the contribution of the NO metabolite nitrate, we 
added 50 µl vanadium(III) chloride (8 mg/ml in 1M HCL) to the Griess reagent 
and incubated it at 37 °C for 30 min45.
Facial nerve axotomy. We anesthetized 13–16-week-old mice with ketamin/
rompun according to published protocols. The left facial nerve was transected 
at the stylomastoid foramen, and the animals were killed using CO2 after a 
survival time of 7 d22. Successful axotomy was assumed on the basis of immo-
bile whiskers on the lesioned side. GCV administration started 1 week before 
axotomy. Facial nerve axotomy experiments were approved by the UK Home 
Office (PPL 70/5341 to G.R.).
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Note: Supplementary information is available on the Nature Medicine website.
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Dendritic cells permit immune invasion of the CNS in an 
animal model of multiple sclerosis
Melanie Greter1, Frank L Heppner2, Maria P Lemos3, Bernhard M Odermatt4, Norbert Goebels1, Terri Laufer3, 
Randolph J Noelle5 & Burkhard Becher1
Immunization with myelin antigens leads to the development of experimental autoimmune encephalomyelitis, an animal model of 
multiple sclerosis. The disease can also be induced by the transfer of encephalitogenic CD4+ T helper (TH) lymphocytes into naive 
mice. These T cells need to re-encounter their cognate antigen in the context of major histocompatibility complex (MHC) class 
II–bearing antigen-presenting cells (APCs) in order to recognize their target. The cell type and location of the APC mediating 
T-cell entry into the central nervous system (CNS) remain unknown. Here, we show that APCs of the lymphoreticular system 
and of the CNS parenchyma are dispensable for the immune invasion of the CNS. We also describe that a discrete population 
of vessel-associated dendritic cells (DCs) is present in human brain tissue. In mice, CD11c+ DCs alone are sufficient to present 
antigen in vivo to primed myelin-reactive T cells in order to mediate CNS inflammation and clinical disease development.
Multiple sclerosis is the most common inflammatory disease of the 
CNS, which is characterized by perivascular inflammatory lesions, 
demyelination and axonal damage1. Experimental autoimmune 
encephalomyelitis (EAE) serves as the animal model of multiple 
sclerosis and can be induced in susceptible rodent strains by active 
immunization with myelin antigens. During EAE, auto-aggressive 
myelin-reactive T lymphocytes migrate into the CNS, where they 
recognize their cognate target antigen and initiate an inflammatory 
cascade leading to tissue damage. The disease can also be induced by 
adoptively transferring an expanded population of myelin-reactive 
encephalitogenic CD4+ TH cells. Although the molecular require-
ments for naive T-cell priming and the formation of an immunologic 
synapse between a naive T cell and a competent APC are well charac-
terized2, little is known about the APC requirements of fully primed, 
activated TH cells. Because even activated and expanded T cells cannot 
recognize native proteins in the absence of APCs, encephalitogenic 
TH cells that enter the CNS need to re-encounter their cognate APCs 
in order to identify their target3. Oligodendrocytes are myelinating 
cells of the CNS and are thought to be the main target of such an 
antimyelin immune response. But oligodendrocytes do not express 
MHC class II molecules and can therefore not serve as APCs4,5. It is 
commonly believed that CNS-resident microglia or astroglial cells 
serve as local APCs to permit target recognition for invading lympho-
cytes6,7. This assumption is mainly based on in vitro studies and the 
identity of the CNS-resident APCs that are crucial for T-cell reactiva-
tion and disease onset and progression in vivo is a subject of intense 
debate6,8–10.
Upon adoptive transfer of activated myelin-reactive T cells into 
recipient animals, there is a lag phase of several days before their inva-
sion of the CNS and the development of clinical disease11,12. This lag 
phase has been interpreted to represent a crucial time period during 
which disease-causing T cells are reactivated. Attempting to show the 
crucial antigen-presenting events that occur during this lag phase, 
researchers have performed trafficking studies of myelin-reactive T 
cells. It was shown that myelin basic protein–reactive lymphocytes 
transferred into rats first enter secondary lymphoid tissues, where 
the expression of activation markers and chemokine receptors is 
synchronized before CNS entry11. Although these studies suggested 
a causal involvement of the peripheral immune system in inducing 
encephalitogenic activity of adoptively transferred effector T cells, an 
essential role of the systemic immune compartment in CNS inflam-
mation and disease development was not established. Here we show 
that encephalitogenic T cells migrate into the CNS, recognize their 
target antigen and cause disease even in the absence of a lympho-
reticular system. Furthermore, MHC class II–bearing cells within 
the CNS parenchyma, such as microglia, are not required to serve as 
APCs permitting lymphocyte entry and disease development. Using 
transgenic mice in which the APC capacity is restricted to DCs, we 
establish that a population of CD11c+ (encoded by Itgax) DCs is suf-
ficient to present antigen to autoreactive T cells in order to mediate 
CNS inflammation and clinical disease development. The presence 
of CD209 (DC-SIGN)+ cells in close proximity to invading T cells 
in acute and chronic active human multiple sclerosis lesions further 
corroborates these findings.
1Neuroimmunology Unit, Department of Neurology, University Hospital Zurich, Frauenklinkstrasse 10, CH-8091 Switzerland. 2Institute of Neuropathology, 
Department of Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091 Switzerland. 3Division of Rheumatology, University of Pennsylvania, 421 
Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. 4Institute for Clinical Pathology, Department of Pathology, University Hospital Zurich, Haeldeliweg 4, 
CH-8091 Switzerland. 5Department of Microbiology and Immunology, Dartmouth Medical School, 1 Medical Center Drive, Lebanon, New Hampshire 03755, USA. 
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RESULTS
Lymphocyte migration into the CNS is independent of lymphoid 
organs
It has been shown that upon adoptive transfer of encephalitogenic T cells 
into naive recipients, the T cells first migrate into secondary  lymphoid 
tissues, where they evidently receive further maturation signals before 
CNS invasion11. To establish whether the lymphoreticular system 
is  functionally involved in the guidance of committed autoreactive 
T cells into the CNS, we adoptively transferred myelin  oligodendrocyte 
 glycoprotein (MOG)35-55 peptide–reactive lymphocytes into Map3k14
aly 
(also known as alymphoplasia or aly) mice. Map3k14aly mice, which 
carry a point mutation in the NF-κB-inducing kinase (NIK, encoded 
by Map3k14), are characterized by the complete absence of lymph 
nodes and Peyer’s patches, and show a disorganized thymic and splenic 
 architecture13. To further rule out splenic  involvement in the T-cell 
homing process, we splenectomized Map3k14aly mice before transfer-
ring MOG- reactive  lymphocytes. Map3k14aly mice (Fig. 1a) as well 
as  splenectomized Map3k14aly mice (Fig. 1b) are fully susceptible to 
 adoptively  transferred EAE when compared to wild-type control mice 
(Fig. 1). Using flow  cytometry, we further show that the degree of CNS 
inflammation during peak disease is not diminished in the adoptively 
transferred,  splenectomized Map3k14aly mice  compared to wild-type 
recipients (Fig. 1c). Before CNS infiltration, adoptively transferred 
lymphocytes seem to initially migrate into secondary  lymphoid tissues 
(Supplementary Fig. 1 online). But in the absence of a  lymphoreticular 
system (splenectomized Map3k14aly) adoptively transferred T cells can 
mainly be found in the blood before they invade the CNS (Supplementary 
Fig. 1 online). Our data show that the migration of encephalitogenic 
T cells to secondary lymphoid tissues is not a  prerequisite for the 
 conditioning of auto-aggressive T cells before their migration into the 
CNS and the development of disease.
CNS-resident APCs do not present antigen in vivo
The above data implicate MHC class II–expressing APCs outside of 
 secondary lymphoid sites as crucial for the development of EAE. With 
regard to the CNS, evidence has been presented that microglia10,14,15 as 
well as astroglial cells7 are capable of presenting antigen. Particularly, 
CNS-resident microglia have been shown to be potent APCs in vitro 
and are widely held to mediate target recognition of encephalitogenic T 
cells14–17, although these findings have been challenged by others9.
To dissect whether APCs in the CNS parenchyma or in the periphery 
present antigen to encephalitogenic T cells, we combined bone  marrow 
chimerism with gene targeting as described earlier18,19. To track the 
 reconstitution with bone marrow–derived elements we injected  congenic 
bone marrow (C57BL/6-CD45.1) into lethally irradiated C57BL/6-
CD45.2 recipient mice. Two months after reconstitution of wild-type 
mice with congenic bone marrow, cytofluorometric analysis of CNS 
mononucleated cells showed that microglia (CD45lo/CD11b+) were of 
host origin, whereas CD45hi CNS-associated leukocytes were of donor 
origin (Fig. 2a). Detailed immunocytochemical analysis confirmed that 
CD45.1+ donor-derived cells were associated with blood vessels, but not 
the CNS parenchyma (Fig. 2b), consistent with reports by others20,21.
In contrast to the radio-resistant CNS, the peripheral immune system is 
readily repopulated by cells derived from the donor bone marrow. MHC 
class II–bearing cells including B lymphocytes, DCs, monocytes, macro-
phages and polymorphonuclear cells within lymph nodes, spleen and blood 
are almost exclusively of bone marrow–donor genotype as assessed by flow 
cytometry and immunohistochemistry (Supplementary Fig. 2 online).
To restrict capable APCs to either the CNS or peripheral immune 
 compartment, we generated a combination of bone marrow chimeras 
using MHC class II–deficient (H2-Ab1–/–, also known as IAβb–/–) mice. 
Adoptive transfer of MOG-reactive lymphocytes into bone marrow chi-
meras with CNS-restricted MHC class II expression (H2-Ab1–/– → H2-
Ab1+/+) does not lead to CNS invasion and disease development (Fig. 
2c,d). Notably, MHC class II expression restricted to the systemic immune 
compartment (H2-Ab1+/+ → H2-Ab1–/–) was permissive for disease devel-
opment. The data indicate that CNS-resident APCs such as microglia or 
astrocytes are not required for T cells to recognize their cognate antigen 
in vivo. Even though secondary lymphoid tissues are not crucial for the 
migration of T cells into the CNS, reconstituting H2-Ab1–/– mice with 
H2-Ab1+/+ bone marrow restored EAE susceptibility. We observed slight 
but significant differences between the susceptible groups (P < 0.05, days 
13–17). The turnover of perivascular cells from the periphery into the CNS 
in bone marrow chimeric mice occurs over several weeks, as previously 
shown, whereas microglial replacement by fresh bone marrow emigrants 
is negligible22. Hence, the incomplete reconstitution of vessel-associated 
MHC class II–positive cells 6–8 weeks after bone marrow transfer readily 
explains the decrease in  inflammation and clinical severity of bone mar-
row chimeras in which MHC class II molecules are absent from the CNS. 
Taken together, the data suggest that a radio-sensitive APC outside of the 
CNS parenchyma is obligatory for disease development.
MHC class II–positive DCs permit EAE development
Several recent reports claim that DCs not only migrate into the CNS 
during inflammation in multiple sclerosis lesions23, but can also be 
found to associate with the blood-brain barrier and the meninges under 
a b
c
Figure 1  Secondary lymphoid tissues are not a pivotal homing site for 
encephalitogenic lymphocytes. (a) EAE was induced by adoptive transfer 
of MOG-reactive lymphocytes into Map3k14aly (filled triangle) or wild-type 
(Map3k14+/aly) mice (open square). (b) As in a, but using splenectomized 
Map3k14aly mice (filled triangle) or wild-type mice (open square). No 
significant difference in the severity of the disease could be detected 
between the different groups. Shown is one representative of three 
experiments (n = 6 mice/group). (c) To quantify CNS infiltrates, CNS 
mononuclear cells from a group of four mice were isolated on day 20 after 
transfer as described and stained with antibodies to CD45 and CD11b 
and analyzed by flow cytometry. CD45 is used to distinguish CNS-resident 
microglia (CD45lo) from invading leukocytes (CD45hi). The CD45hi cells 
are further distinguished by their expression of CD11b (macrophages and 
granulocytes) or lack thereof (lymphocytes). Naive C57BL/6 mice were used 
as a negative control.
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physiologic conditions24–26. To determine whether DCs are sufficient to 
support the reactivation of fully primed MOG-reactive encephalitogenic 
T cells in vivo, we used mice in which H2-Ab1 expression was targeted 
specifically to the DCs of H2-Ab1–/– mice. Expression of H2-Ab1 under 
the control of the CD11c promoter (hereafter transgenic mice referred 
to as CD11c–H2-Ab1/H2-Ab1–/–) has been shown to be restricted to 
DCs27,28. Fig. 3a,b shows the distribution of MHC class II and CD11c 
in the spleen of CD11c–H2-Ab1/H2-Ab1–/– compared to H2-Ab1+/+ and 
H2-Ab1–/– mice. As expected, we were not able to detect any expression 
of MHC class II molecules within the CNS parenchyma of CD11c–H2-
Ab1/H2-Ab1–/– mice (Fig. 3c). MHC class II–positive cells, although 
small in number, were restricted to the meninges and vessels (Fig. 3c). 
Adoptive transfer of MOG-reactive lymphocytes into these mice showed 
that CD11c-driven H2-Ab1 expression fully restores EAE susceptibility 
in H2-Ab1–/– mice (Fig. 4a). Fig. 4b shows the inflammatory lesions 
correlating with H2-Ab1 expression. Taken together, CD11c+ DCs, even 
in the absence of other MHC class II–expressing cell types, are sufficient 
to permit disease development and CNS inflammation upon adoptive 
transfer of encephalitogenic T lymphocytes.
To determine whether an analogous population of CNS- associated 
DCs can also be found in human CNS tissue, we analyzed brain 
 tissue obtained from multiple sclerosis patient autopsy material with 
 confirmed diagnosis of acute or chronic active multiple sclerosis, as 
well as from noninflamed control tissue. As expected, within multiple 
sclerosis plaques we found a variety of immune cells including T cells 
(CD3, CD4), macrophages (CD68, CD163) (Fig. 5) and B cells/plasma 
cells (CD20, CD38, CD138) (data not shown). In addition, the inflamed 
tissue shows a drastic upregulation of human leukocyte antigen (HLA) 
class II molecules. In accordance with a previous study23, we could also 
detect CD209 (DC-SIGN)+ cells—a marker reported to be restricted 
to DCs29—in close proximity to invading T cells (Fig. 5). Notably, 
CD209+ cells were also found in noninflamed human brain tissue  lining 
blood vessels, leading to the idea that they may act as the initial APCs 
 recognized by invading encephalitogenic T cells.
Augmenting the number of DCs increases clinical severity
Given that DCs alone seem to be sufficient to allow T-cell target 
 recognition and disease development during EAE, we determined 
a
c d
b Anti-CD45.2 (host) Anti-CD45.1 (donor)
100 µm
20 µm
Figure 2  MHC class II molecules in the CNS parenchyma are not crucial for the development of EAE. Lethally irradiated C57BL/6-CD45.2 mice were 
reconstituted with bone marrow cells of C57BL/6-CD45.1 mice. Reconstitution of the CNS in bone marrow chimeras by donor-derived hematopoietic cells 
was determined by FACS analysis (a). Cells present in the spinal cords of C57BL/6-CD45.1 → C57BL/6-CD45.2 bone marrow chimeras were analyzed by flow 
cytometry. Cells were stained with antibodies to CD45 and CD11b (R2, CD45lo/CD11b+ microglia; R3, CD45hi/CD11b– lymphocytes; R4, CD45hi/CD11b+ 
macrophages and granulocytes). CNS-resident (R2) and associated cells (R3, R4) were further analyzed for the expression of the donor (CD45.1) versus host 
congenic marker (CD45.2) (right). (b) Frozen brain tissue of C57BL/6-CD45.1 → C57BL/6-CD45.2 was sectioned and stained for either the donor marker 
(CD45.1) or the host marker (CD45.2). Low magnification overviews (upper) and higher magnifications (lower). Donor-derived cells were restricted to blood 
vessels. (c) EAE was induced in bone marrow chimeras by adoptive transfer. Bone marrow chimeras lacking MHC class II molecules in the systemic immune 
compartment (H2-Ab1–/– → H2-Ab1–/–, open circle; H2-Ab1–/– → H2-Ab1+/+, filled inverted triangle) are resistant to the induction of EAE. Bone marrow 
chimeras expressing MHC class II molecules in the systemic immune compartment (H2-Ab1+/+ → H2-Ab1+/+, filled upright triangle; H2-Ab1+/+ → 
H2-Ab1–/–, open square) are susceptible to EAE. Shown is one representative of three experiments (n ≥ 6 mice/ group). (d) Hematoxylin and eosin staining of 
spinal cord sections of bone marrow chimeras 10 d after disease onset. The tissue location of the higher magnification image is indicated by a rectangle.
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whether the limited number of suitable APCs is rate limiting and respon-
sible for the lag phase between adoptive transfer of encephalitogenic 
T cells and CNS infiltration. We used recombinant FMS-like tyrosine 
kinase 3 ligand Flt-3L:IgG, a growth factor for DCs30,31, to stimulate DC 
 expansion. Upon systemic injection of (Flt-3L):IgG into recipient mice 
for 10 d, the number of DCs rose considerably in the lymphoreticular 
 system. As for the CNS, we observed an increase of DCs in the meninges 
(Fig. 6a and Supplementary Fig. 3 online). Detailed analysis shows that 
these DCs are predominantly CD11b+ myeloid DCs and have a mature 
phenotype as judged by the expression of CD80, CD86 and MHC class 
II (Supplementary Fig. 3 online).
At day 5 of Flt-3L:IgG treatment, recipi-
ents were injected with MOG-reactive 
 lymphocytes. Flt-3L:IgG-treated mice showed 
a  substantial increase in disease severity 
(Fig. 6b). Lymphocyte infiltration was 
increased by ∼30% as judged by the 
 number of CD45hi lymphocytes isolated 
from the CNS of Flt-3L:IgG-treated EAE 
mice (Supplementary Fig. 3 online). To 
 eliminate the potential role of Flt-3L:IgG as 
an  adjuvant for bystander lymphocytes, we 
transferred encephalitogenic lymphocytes into Flt-3L:IgG-treated 
 recombinase activating gene 1 (Rag1)-deficient mice (Fig. 6c), which 
lack mature lymphocytes, as well as to splenectomized Map3k14aly 
mice (Supplementary Fig. 3 online). Notably, Flt-3L:IgG treatment 
was found to condense the time span between adoptive transfer and 
 disease onset and increased disease severity. In the inflamed brain 
tissue, T cells and DCs colocalize and Flt-3L:IgG treatment increased 
the size of the  inflammatory lesion (Fig. 6d).  These data corroborate 
our findings that DCs are the most, if not the only,  critical population 
of APCs conferring CNS  inflammation and  disease  development by 
 encephalitogenic lymphocytes. 
a
b
c
Figure 3  Localization of MHC class II–expressing 
cells in CD11c–H2-Ab1/H2-Ab1–/– mice. 
Spleen cryosections were prepared from H2-
Ab1+/+, CD11c-H2-Ab1/H2-Ab1–/– mice, and 
H2-Ab1–/– mice and stained with monoclonal 
antibodies against (a) MHC class II (M5/140), 
(b) CD11c. Staining shows a typical distribution 
of DCs in the spleen of CD11c–H2-Ab1/H2-
Ab1–/– mice. Scale bar, 100 µm. (c) In brain 
sections, MHC class II can not be detected in 
the CNS parenchyma of CD11c–H2-Ab1/H2-
Ab1–/– mice but on DCs located at the meninges 
or perivascular sites (arrows). Scale bar, 50 µm.
a b
Figure 4  DC-restricted MHC class II expression is 
sufficient to permit disease development. MOG-
reactive lymphocytes were injected into either H2-
Ab1+/+, H2-Ab1–/– or CD11c–H2-Ab1/H2-Ab1–/– mice. 
(a) Whereas H2-Ab1–/– mice did not develop clinical 
EAE (filled inverted triangle), H2-Ab1+/+ (filled 
upright triangle) as well as CD11c–H2-Ab1/H2-Ab1–/– 
(open square) mice were equally susceptible to EAE. 
Shown is one representative of three experiments, 
n ≥ 6 mice/group. (b) Ten days after disease onset, the 
mice were killed and CNS tissues were cryopreserved. 
Adjacent cerebellar sections were stained with 
monoclonal antibodies against MHC class II or CD11c 
and compared to hematoxylin and eosin–stained 
sections. Scale bar, 100 µm.
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DISCUSSION
Given that oligodendrocytes are not capable of presenting antigen to 
encephalitogenic CD4+ TH cells
4, an APC as a compulsory ‘third party’ 
is required for target recognition by encephalitogenic T cells to initiate 
EAE. There are three major sites at which adoptively transferred encepha-
litogenic lymphocytes can encounter competent APCs: (i) the systemic 
immune compartment with its secondary lymphoid tissues, (ii) the CNS 
parenchyma harboring microglia and astrocytes, (iii) the perivascular and 
meningeal space with its macrophages and DCs.
There is an enduring debate regarding the anatomic site responsible 
for the reactivation of encephalitogenic T cells and the development of 
disease. The importance of T-cell reactivation in the peripheral immune 
compartment is one issue, and the functional role of CNS APCs is 
another. With regard to the systemic immune compartment, the fate 
of encephalitogenic lymphocytes upon adoptive transfer into recipient 
animals remains unresolved. The normal homing behavior of transferred 
T cells seems to direct them into secondary lymphoid sites prior to CNS 
invasion11. It was shown that myelin-specific lymphocytes transferred 
into rats first enter secondary lymphoid tissues, where the expression 
of activation markers is synchronized before CNS entry11. In particular, 
myelin-specific lymphocytes entering secondary lymphoid tissues evi-
dently mature within such a lymphoid environment as they upregulate 
chemokine receptors like CCR1, CCR3, CCR5 and CXCR4 (ref. 11). Our 
results confirm that in the presence of secondary lymphoid sites, enceph-
alitogenic lymphocytes predominantly migrate into these organs, but this 
migration pattern is not essential to ultimately invade the CNS. We show 
that even in the complete absence of lymph nodes, Peyer’s patches and 
spleen, encephalitogenic lymphocytes still find their way into the CNS 
and initiate tissue destruction with similar kinetics as seen in wild-type 
mice showing a normal lymphoreticular environment.
Within the CNS, astrocytes and endothelial cells, in principle, are 
capable of expressing MHC class II molecules, but their capacity to act 
as competent APCs remains  speculative6,32. 
Although CNS-resident astrocytes have 
been suggested to potentially act as APCs for 
 invading T cells33, transgenic targeting of MHC 
class II expression to astrocytes did not support 
target recognition by encephalitogenic T cells 
in vivo32. Microglia and macrophages are generally considered the most 
 prominent CNS-resident APCs and their capacity to present antigen in 
vitro has been repeatedly shown by several independent groups, including 
ours15–17,34,35. Furthermore, we and others have recently reported that 
lymphocyte-induced activation of microglia in vivo is crucial for immune 
infiltration of the CNS and the maintenance of encephalitogenicity dur-
ing the effector phase of EAE18,19,36,37.  To seek proof whether microglia 
are also capable of presenting antigen to auto-aggressive effector T cells in 
vivo, we restricted MHC class II expression either to the CNS parenchyma 
or to the peripheral immune compartment and the blood-brain barrier 
and meninges. Although microglia are vital components of the effec-
tor phase in EAE, the data presented here show that neither microglia, 
nor any other parenchymal elements are required to mediate cognate T 
cell–APC interactions in vivo. This conclusion can be drawn from the 
experiments using MHC class II bone marrow chimeras as well as using 
mice in which MHC class II expression was restricted to DCs.
Our data show that MHC class II expression restricted to DCs is per-
missive for full disease development induced by adoptive transfer of 
encephalitogenic lymphocytes. Taken together with the observation that 
neither secondary lymphoid tissues nor CNS-resident cells are required or 
sufficient to permit EAE development, we postulate that a population of 
DCs associated with the meninges and CNS blood vessels allows encepha-
litogenic T cells to recognize their cognate antigen leading to CNS inva-
sion, inflammation and ultimately neurologic deficit. Although DCs seem 
to be completely absent from the CNS parenchyma under physiological, 
nonpathological conditions,  several groups showed the presence of DCs 
in the meninges and choroid plexus of rodents7,23–25. We confirmed the 
presence of DCs at the blood-brain barrier and meninges in mice, and 
analogous CD209+ cells were found in noninflamed human brain tissue, 
suggesting that initial antigen presentation could potentially occur at the 
blood-brain barrier, thus promoting entry of T cells into the CNS25,38,39. 
Under  physiologic  conditions, DCs  associated with CNS vessels could pro-
a
b
Figure 5  Presence of vessel-associated CD209+ 
cells in multiple sclerosis lesions (a) CNS 
tissue of multiple sclerosis patient autopsy 
material displaying a subcortical chronic active 
multiple sclerosis lesion characterized by severe 
demyelination (HE, hematoxylin and eosin; LN, 
Luxol-Nissl) and numerous CD163+ or CD68+ 
macrophage and microglia–rich inflammatory 
infiltrates including prominent perivascular 
inflammation (third and fourth upper panel). 
Control autopsy material (lower panels); no 
inflammatory infiltrates were observed and 
CD163 and CD68 show vessel-associated 
macrophages. Gray (bottom) and white matter 
(top) in first and second column is separated by 
asterisks. Rectangles represent the area chosen 
for higher-magnification analysis throughout. 
(b) Although strong HLA class II immunoreactivity 
was present throughout the multiple sclerosis 
lesion, CD209+ cells were vessel-associated and 
seen in close proximity to invading CD3+ and 
CD4+ T cells. In noninflamed tissue, CD209+ 
cells were found exclusively associated with blood 
vessels. Scale bar, 400 µm, first and second 
column in a; 100 µm for all other panels.
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cess and  present myelin antigens in the  context of MHC class II  molecules. 
Their maturation state under physiologic conditions may not be  sufficient 
to drive naive T cells, but would be adequate to restimulate adoptively 
transferred antigen- experienced effector cells to recognize their cognate 
antigen. Alternatively, under pathological conditions, it is feasible that 
DCs migrate into the CNS in order to act as APCs for comigrating T cells. 
Inflammatory foci in the CNS arrange in a fashion similar to secondary 
lymphoid organs38,39, and other studies indicate that epitope spreading 
occurs exclusively within the inflamed CNS40, suggesting that the CNS 
could act as a neolymphoid tissue. To underline the vital role of DCs to 
provide target recognition cues for committed encephalitogenic T cells, 
we could show that increasing the number of available DCs substantially 
increases the severity of clinical symptoms. It is widely held that like EAE, 
the pathogenesis of multiple sclerosis is mainly driven by CNS-invading 
encephalitogenic TH cells. Although EAE is an inducible rather than spon-
taneous model for multiple sclerosis, clearly limiting its translatability to 
the human disease, fundamental mechanisms, such as antigen recognition, 
are not likely to differ considerably between humans and mice. We propose 
that DCs, strategically located between the immune system and CNS, act 
as sentinels for the CNS, scanning for physiologic self or infectious foreign 
antigens and, as part of the normal immune surveillance and protection 
of the CNS, present these to cognate T cells migrating through CNS ves-
sels. Thus, DCs at the interface of the CNS and the immune system are 
pivotal players in the development of CNS inflammation and could serve 
as a novel therapeutic target for the treatment of patients with multiple 
sclerosis and other inflammatory diseases of the CNS.
METHODS
Mice. C57BL/6 and C57BL/6-CD45.1 mice were purchased from Harlan 
Laboratories. The following mice were bred in house under specific pathogen-
free conditions: Rag1–/–, CD11c–H2-Ab1/H2-Ab1–/–, H2-Ab1–/–, Map3k14aly. 
Heterozygous Map3k14+/aly mice were used as a control for Map3k14aly mice. 
Bone marrow chimeras were generated as described previously18,19. After 
recovery, bone marrow chimeras were bled retro-orbitally to ensure more than 
95% engraftment of blood leukocytes. All experiments involving animals were 
approved by the Swiss Kantonal Veterinary office (2003/68). 
Flt-3L:IgG treatment of mice. Flt-3L:IgG was purchased from BioExpress. Mice 
were treated with Flt-3L:IgG (10 µg/mouse/d) for 10 d consecutively. In adop-
tive-transfer EAE experiments, mice were treated with Flt-3L:IgG for 5 d before 
adoptive transfer. Flt-3L:IgG treatment was continued for an additional 5 d.
Splenectomy. We anesthetized mice using an isoflurane inhalator. A 0.5-cm skin 
incision was made at the level of the thirteenth rib, the spleen was exposed by 
opening the abdominal wall and exteriorized through the incision. We ligated 
blood vessels using four nylon sutures and removed the spleen. The peritoneal 
wall and the skin incision were closed with Indermil tissue adhesive glue (Tyco 
Healthcare). We treated mice with 5 µg/g body weight flunixin subcutaneously 
for 2 d and 0.75% Borgal in the drinking water for 7 d after surgery.
Induction of EAE. We obtained MOG35–55 peptide (amino acid sequence: 
MEVGWYRSPFSRVVHLYRNGK) from Research Genetics. MOG35–55-reactive 
lymphocytes were generated as described18. Cells were injected into recipient mice 
(20–30 × 106 cells/mouse). We administered pertussis toxin to mice (200 ng/mouse) 
on day 0 and 2 ng/mouse after transfer. Mice were scored as follows: 0, no detectable 
signs of EAE; 0.5, distal limp tail; 1, complete limp tail; 1.5, limp tail and hind limb 
weakness; 2, unilateral partial hind limb paralysis; 2.5, bilateral partial hind limb 
paralysis; 3, complete bilateral hind limb paralysis; 3.5, complete hind limb paralysis 
and unilateral forelimb paralysis; 4, total paralysis of fore and hind limbs (score > 
4, to be killed); 5, death. Each time point shown is the average disease score of each 
group ± s.e.m. Statistical significance was assessed using a unpaired Student t-Test.
Histology. Whole mouse brains or spinal columns were fixed in 4% paraformal-
dehyde in phosphate-buffered saline and paraffin-embedded or freshly snap-
frozen in liquid nitrogen according to standard protocols. We used the following 
mouse-specific antibodies: CD11c (Jackson ImmunoResearch Labs), MHC class 
II (M5/114, American Type Culture Collection) CD3, CD45.1, CD45.2 (BD 
Pharmingen). Primary antibodies were shown by sequential incubation with 
goat antibodies against species-specific immunoglobulins, followed by alkaline 
phosphatase–labeled donkey antibodies against goat immunoglobulins (Jackson 
ImmunoResearch). We visualized alkaline phosphatase using naphthol AS-BI 
(6-bromo-2-hydroxy-3-naphtholic acid-2-methoxy anilide) phosphate and new 
fuchsin as substrate. Endogenous alkaline phosphatase was blocked by levamisole. 
b c
d
a Figure 6  Augmenting the number of DCs increases EAE severity. 
(a) C57BL/6 mice were treated with (Flt-3L):IgG as described29. 
Cryosections of brains were stained using monoclonal antibodies against 
CD11c, showing a strong increase of immunoreactivity in the meninges of 
(Flt-3L):IgG-treated mice. Scale bar, 50 µm. (b) C57BL/6 mice or 
(c) Rag1–/– mice were treated with (Flt-3L):IgG for 5 d before adoptive 
transfer of MOG-primed lymphocytes. Treatment with Flt-3L:IgG was 
continued for an additional 5d. (b,c) Mice treated with (Flt-3L):IgG (filled 
square or triangle) develop significantly more severe EAE than mock-treated 
control mice (open circle). In b, P < 0.05, days 10–20. In c, P < 0.05, days 
8–17. Shown is a representative of three individual experiments (n ≥ 6 
mice/group). (d) Mice were killed and CNS tissues were cryopreserved 10 d 
after disease onset. Staining for CD3 and CD11c shows that inflammatory 
T cells colocalize with DCs in the inflamed brain. Scale bar, 100 µm.
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Color reactions were performed at room temperature (21–23 °C) for 15 min with 
reagents from Sigma Chemical Co. We counterstained sections with hemalum 
and mounted coverslips with glycerol and gelatin.
Formalin-fixed and paraffin-embedded human autopsy material of acute, 
chronic active and chronic inactive multiple sclerosis cases as well as age-matched 
controls without neuropathological alteration was used. Informed consent for 
autopsy was given by the relatives. All cases underwent detailed neuropathologic 
examination. We performed hematoxylin and eosin and Luxol-Nissl stains accord-
ing to standard procedures. Immunohistochemical stains were carried out on 
an automated Nexus staining apparatus (Ventana Medical Systems), following 
the manufacturer’s guidelines. We used antibodies to human CD8, CD20, CD68, 
CD79a, CD138 (all DAKO), CD4, CD38, CD163, HLA DR,DP,DQ (MHC class II; 
all Novocastra Laboratories Ltd.), CD3 (Labvision) and CD209 (R&D Systems).
Flow cytometry. For cytofluorometric and immunohistochemical analysis, 
we used the following antibodies: CD45-pan, CD45.1, CD45.2, CD11b, CD11c, 
CD80, CD86, H2-Ab1. All antibodies were obtained from BD Pharmingen. 
Cytofluorometric analysis of CNS invading lymphocytes has been described previ-
ously18. Briefly, mice were killed with CO2 and spinal cords were removed by flush-
ing the spinal column with sterile HBSS. We dissected the brain to isolate the brain 
stem. Both tissues were homogenized and strained through a 100 µm nylon filter 
(Fisher). After centrifugation, we resuspended the cell suspension in 37% isotonic 
Percoll and underlayed it with 70% isotonic Percoll. The gradient was centrifuged 
at 600 g for 25 min at room temperature (21–23 °C). We collected the interphase 
cells and extensively washed them before staining. For flow cytometry, the cells 
were stained with primary antibodies (all from BD Pharmingen) for 30 min at 
4 °C, washed and, when required, incubated with streptavidin-coupled fluoro-
chromes (BD Pharmingen) for 15 min. We washed and analyzed the cells using a 
FACSCalibur (BD Pharmingen) with CellQuest software. Post-acquisition analysis 
was performed using WinMDI 2.8 software (Scripps-Research Institute).
Note: Supplementary information is available on the Nature Medicine website.
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DISCUSSION 
 
The sequence of immunopathological events involved in the development of EAE can 
be subdivided into two phases: i) T cell priming/activation, which is initiated by 
systemic immunization with myelin Ags and ii) the subsequent recruitment/effector 
phase, in which primed myelin-reactive T cells reencounter their cognate Ag in the 
target tissue leading to the development of EAE. In this thesis, I have analyzed the 
role of SLTs and their requirement for the “T cell priming phase” and determined the 
cell types, which are necessary and sufficient during the “effector phase” to initiate an 
inflammatory cascade leading to the tissue lesion.  
 
 
T CELL PRIMING PHASE 
 
T CELL PRIMING IN THE ABSENCE OF SLTS  
A fundamental tenet of immunology is the notion that adaptive immune responses are 
generated in SLTs (23). SLTs contain defined B and T cell zones which provide the 
structural requirements for the concerted interaction of immune cells. Nearly 40 years 
ago it was shown that the presence of lymphatic vessels and LNs is a requirement for 
the development of an immune response. Isolated skin flaps were connected to 
recipient guinea pigs. An immune response to the skin-derived Ag was only provoked 
when the skin flaps were connected to the recipients via lymphatic vessels and in the 
presence of LNs (138). Many studies using mutant mice strains have further 
highlighted the pivotal role of these specialized tissues.  LTα-/- mice, which lack all 
LNs, can not mount Ab responses and class switching upon immunization with sheep 
red blood cells (139).  Aly/aly mice, which are also characterized by the absence of all 
LNs and Peyer’s patches, are highly susceptible to VSV infections caused by the 
failure to mount IgG responses (43). The treatment of wt mice with LTβR-Fc protein 
disrupts B cell follicles in SLTs. As a result of the destroyed structures, humoral 
immune responses are suppressed (140). These reports verify that GCs provide a vital 
milieu for the generation of high-affinity Abs and isotype switching. No such 
dedicated structures however are evident for T cell responses. Recent methods using 
intravital microscopy have shed new light on T cell/DC communications within LNs 
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(141). The complex motility behavior of T cells is believed to comprise different 
stages and serial interactions with DCs in SLTs. Nevertheless, only few studies 
provide insight into the SLT-requirement for effective T cell priming. LTα-/- mice do 
not elicit a contact-hypersensitivity reaction in response to epicutaneous hapten 
indicating that LNs comprise a necessity for T cell-mediated immune responses (142). 
It is widely held that immune responses to an allograft are prompted by the actions of 
both CD4+ and CD8+ T cells. However, it has been a subject of debate whether T cell-
mediated immune responses to an allograft are initiated in the allograft itself or in 
SLTs. Several studies speak for the latter hypothesis. Aly/aly and splenectomized 
aly/aly mice are not able to reject allogeneic skin grafts or cardiac allografts 
indicating that the presence of lymphoid tissues is required for the development of an 
allograft response (143,24). Collectively, these studies postulate that expansion of Ag-
specific T cells occurs within SLTs. This notion has also been applied to 
immunization-induced T cell priming.  
We provide irrefutable evidence that in mice lacking SLTs, s.c. immunization with 
foreign as well as auto-Ag can initiate productive T cell priming as well as 
autoimmunity respectively. We could demonstrate that aly/aly mice mount solid 
delayed-type hypersensitivity (DTH) reactions, which is indicative of an effective T 
cell-mediated immune response. We further observed that aly/aly mice are resistant to 
EAE. However, we discovered that this cannot be explained by the developmental 
malformations of aly/aly mice. By generating BM-chimeric mice it was found that the 
NIK mutation abrogates the polarization of IL-17 producing encephalitogenic T cells 
even when the lymphoreticular compartment is unperturbed (NIK-deficient immune 
system and normal SLTs). So far the immunodeficiency observed in aly/aly mice was 
mainly attributed to the absence of LNs but not on the impact of NIK signaling on 
immunity (24,40). We could demonstrate that the immunodeficiency of aly/aly mice 
is disconnected from their structural malformations but due to an intrinsic defect in 
cells of the hematopoietic compartment.  
Surprisingly, aly BM-chimeric mice, which lack all SLTs but harbour a normal 
immune system, are fully susceptible to EAE induced by s.c. immunization with 
MOG. This implies that even in the absence of SLTs, effective T cell priming can be 
initiated. In contrast to the potent T cell priming, humoral immune responses were 
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completely abrogated in these BM-chimeric mice, which was revealed by the absence 
of Ag-specific Abs. 
Taken together, we have challenged the dogma that the initiation of a T cell-mediated 
adaptive immune response only functions in the presence of the structural 
environment of SLTs. As assessed by other groups, for B cell activation, high-affinity 
Abs and class switching, highly organized SLTs are obligatory. In contrast, T cell 
priming is structure-independent. Interestingly, this phenomenon can also be found in 
evolution. B and T cell receptors evolved simultaneously with the emergence of RAG 
in jawed vertebrates. While jawed fish exert adaptive immune functions, GC 
formation and Ig-class switching only evolved in amphibians/birds concomitant with 
the development of LNs. We have therefore recreated the immune-evolutionary stage 
of cold-blooded vertebrates in mice to prove that modern B cells are dependant on the 
topography of lymphoid tissues while T cells retain the capacity to recognize Ag in a 
structure-independent fashion.  
 
ALTERNATIVE SITES FOR T CELL PRIMING 
The question whether adaptive immune responses can be initiated in LN-deficient 
mice was investigated by several groups. In a study where LTα-/- mice were used, 
CD8+ T cell and B cell immunity to virus was elicited, the response was however 
delayed (144). Consistent with this result, we have also noted a delay in the 
proliferation of Ag-specific T cells in aly/aly mice. These findings were attributed to 
the lack of LNs (in aly/aly and LTα-/-) but did not exclude the spleen as a 
compensatory organ for T cell priming. Fu et al. have demonstrated that LTα-/- and 
splenectomized LTβR-/- mice (lack all SLTs) were able to reject allogeneic skin grafts 
and cardiac allografts albeit with delayed kinetics in comparison to wt mice. They 
concluded that LNs are critical for the rejection of allografts but at the same time 
dispensable (145,146). Whether the allograft itself provides a T cell priming site 
remains to be shown. The discrepancy between LTα-/-/LTβR-/- mice and aly/aly mice, 
which were not able to reject allogeneic grafts (41), is in agreement with our results. 
We assessed that the immunodeficiency seen in aly/aly mice can not be explained 
solely based on the absence of LNs and the structural alteration in the spleen.  
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Recently Mori et al. have analyzed whether the altered homing behavior of T cells 
into SLTs has an effect on the development of T cell immune responses (147). 
Paucity of LN T cell (plt) mice, which lack CCL21 and CCL19, display T cell 
migration defects into LNs. Despite the abrogated T cell zone, splenectomized plt 
mice exhibit delayed but effective T cell priming. This indicates that T cell priming 
can occur outside of dedicated T cell zones.  
The question at which alternative site T cell priming could arise in mice lacking all 
SLTs was addressed by Schirrmacher et al. They demonstrated that BM as a primary 
lymphoid organ provides a potential site for T cell priming. Naïve ovalbumin-TCR 
transgenic CD4+ (OTII) and CD8+ (OTI) T cells were transferred into either wt or 
splenectomized aly/aly mice. The cells were found to home to BM (or spleen and LNs 
if present) where they were fully primed by resident DCs in response to blood-borne 
Ag. It was further observed that OTI cells primed in the BM of splenectomized 
aly/aly mice can elicit protective anti-tumor immunity. The fact that BM facilitates T 
cell priming to blood-borne Ag highlights again the dispensability of conventional 
SLTs.  
Upon respiratory infections or inflammation in the lung, the generation of inducible 
bronchial associated lymphoid tissues (iBALT) can be observed. It was reported that 
such a rapid formation of iBALTs could be induced in splenectomized LTα-/- mice 
upon intranasal injections of influenza virus (31). These iBALTs contained defined T 
and B cell areas which conducted effective T and B cell priming leading to clearance 
of the virus. Together, these reports emphasize our discovery that adaptive immunity 
can occur outside of dedicated lymphoid structures. We showed for the first time the 
induction of successful T cell priming and autoimmunity upon s.c. immunization in 
mice lacking SLTs. We demonstrated that the liver could potentially serve as a site for 
the development of T cell-mediated immune responses in the absence of SLTs. By 
using fluorescently coupled microspheres, it was shown that the Ag is carried by local 
APCs from the site of immunization into the liver when SLTs are absent. In the liver, 
the accumulation of Ag-specific TCR transgenic T cells was detected and endogenous 
IFNγ secreting cells specific for the Ag used in the immunization. In mammals, early 
fetal hematopoiesis takes place in the liver. It is possible that the adult liver is 
reminiscent of this function and can substitute regular SLTs when they are not 
available.  
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LYMPHOID NEOGENESIS 
Tissues affected in autoimmune diseases such as MS, rheumatic arthritis and 
Hashimoto thyroiditis often contain TLTs (26). These ectopic lymphoid aggregates 
comprise distinct B cell compartments including GCs with FDCs and T cell 
compartments similar to the micro-architecture in SLTs. In MS, such lymphoid-like 
structures were identified in the meninges containing B cells, T cells and FDCs (148).  
Aloisi et al. investigated whether such TLTs are involved in the progression and 
maintenance of EAE. EAE-diseased mice were treated with LTβR-Fc protein, which 
is known to disrupt lymphoid structures (140). They demonstrated that the LTβR-Fc 
treatment prevents relapses, T cell infiltration and the development of meningeal 
lymphoid follicles (149). It remains to be shown whether this observation is solely 
mediated by the disrupted LTβR pathway or due to an additional inhibition of LIGHT 
(150), which also binds LTβR and is implicated in T cell responses.  
All our data pointed towards the liver as an alternative priming site in mice lacking 
SLTs. We discovered such lymphoid-like structures in the livers of SLT-deficient 
mice upon s.c. immunization with auto- or foreign Ag. Thus in the absence of SLTs, 
TLTs could substitute conventional SLTs and induce T cell priming locally. The 
ectopic structures in the livers contained mainly T cells and DCs and in contrast to 
other reports, only few FDCs and GCs. The fact that no GCs were detected in these 
ectopic lymphoid structures provides an explanation for the absence of Ag-specific 
Abs and proves that humoral immune responses are structure-dependant.  
In order to define whether such newly formed TLTs can serve to propagate T cell 
expansion, we treated wt mice with LTβR-Fc protein. Although the formation of Abs 
and class-switching was eliminated, LTβR-Fc treatment did not influence the disease 
course of EAE. Similar findings were obtained by Gommerman et al. who showed 
that in EAE models requiring pertussis toxin, LT pathway inhibition upon LTBR-Fc 
treatment did not affect EAE development (151). This clearly implies that T cell-
mediated immunity functions structure-independently while B-cell immunity requires 
a proper structural environment. 
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RECRUITMENT AND EFFECTOR PHASE 
 
IDENTIFICATION OF CELL TYPES NECESSARY TO PERMIT IMMUNE INVASION 
OF THE CNS AND DISEASE DEVELOPMENT  
 
Encephalitogenic CD4+ TH cells need to reencounter their cognate Ag in the context 
of MHCII molecules in the target tissue in order to initiate EAE. There are 3 major 
sites at which competent APCs could potentially present myelin-epitopes to 
encephalitogenic T cells: i) the systemic immune compartment with its SLTs, ii) the 
CNS parenchyma harboring microglia and iii) the perivascular and meningeal space 
with its CNS-associated DCs.  
 
APCS RESIDING IN SLTS 
Upon adoptive transfer of MOG-reactive T cells into recipient mice a lag period of 
several days can be observed prior to CNS invasion. Is was shown that myelin-
reactive lymphocytes adoptively transferred into rats, they first migrate to SLTs 
where the expression of activation markers and chemokine receptors is synchronized 
before CNS entry (152). Cervical LNs were proposed to be crucial for the 
development of an immune response to brain-derived Ag (87,153). Their important 
role became further evident by the fact that cervical lymphadenectomy in Lewis rats 
strikingly attenuated cryolesion-induced EAE (154). It was demonstrated that upon i.c 
injection of Ag-loaded DCs, their migration from the CNS into the cervical LNs is 
both necessary and sufficient to activate Ag-specific T cells in order to promote their 
migration into the brain (90). When MBP-reactive T cells were injected intrathecally 
into Lewis rats, they first leave the CNS, become reactivated in the periphery and then 
invade the CNS (134). In summary, these studies indicate that encephalitogenic T 
cells home to (cervical) LNs where they encounter their cognate Ag prior to CNS 
invasion.  
We clearly prove that mice lacking SLTs are fully susceptible to EAE induced by 
either adoptive transfer encephalitogenic T cells or by active s.c. immunization with 
MOG.  Therefore it is evident that SLTs are dispensable for i) the priming of MOG-
reactive T cells and ii) their reactivation preceding CNS invasion. This further 
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indicates that the presence of CNS-Ag as well as CNS-associated APCs in the 
cervical LNs is a result of CNS inflammation but not a driving force.  
 
MICROGLIA – RESIDENT GUARDS OF THE CNS 
Parenchymal microglial cells express all the appropriate restricting elements and co-
stimulatory factors needed to elicit and support T cell responses (155,156,157). In 
many CNS diseases, parenchymal microglial cells are rapidly activated and 
upregulate MHCII, suggesting that they may participate in Ag presentation 
(158,159,160). There is no doubt that within the CNS parenchyma, microglial cells 
are fully equipped to act as APCs. Whether they mediate target recognition of 
encephalitogenic T cells remained to be proven. The observation that microglia are 
resistant to radiation while CNS-associated cells (DCs and macrophages) are radiation 
sensitive has allowed us to dissect the roles of  CNS-endogenous versus CNS-
associated cells in Ag-presentation to T cells in an in vivo setting. By combining BM-
chimerism and gene-targeting, we restricted the APC-capability to either the CNS-
parenchyma (microglia) or the systemic immune compartment. Upon transfer of 
MOG-reactive T cells, chimeras with MHCII expression restricted to the systemic 
immune compartment and CNS-associated cells were susceptible to EAE. However, 
mice with MHCII expression restricted to the CNS-parenchyma were resistant to the 
development of disease. These findings corroborate that cells within the CNS-
parenchyma such as microglia or astrocytes do not serve as APCs permitting T cell 
entry.  
Earlier reports stated that the contribution of microglial cells is vital for the 
development of EAE. In mice in which microglial cells were deficient of the 
costimulatory molecule CD40, infiltration of T cells was impaired and EAE severity 
diminished (117). Furthermore IL-23 secreted by CNS-resident cells is critical for the 
effector phase of EAE (161). In our studies, transgenic mice were used which allowed 
an inducible and transient inhibition of microglia.  We could show that EAE was 
considerably repressed when microglial cells were transiently "paralysed". The 
inhibited activation of microglia led to a reduced inflammation of the CNS. This 
indicates that the release of reactive oxygen species intermediates in addition to 
cytokines and chemokines by activated microglia is vital for the development and 
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maintenance of EAE. Collectively, these observations reveal that while micoglia are 
crucial during the effector phase for the progression of EAE, they are not required to 
participate in Ag-presentation. 
 
CNS-ASSOCIATED DCS – SENTINELS AT THE GATEWAY TO THE CNS 
Under physiological conditions, DCs in the CNS reside in the meninges and the 
choroid plexus but not in the cerebellar parenchyma, brain stem or spinal cord (127) 
(125). Due to the strategically important location, the outermost basal lamina of the 
vessel wall endothelium and the one on top of the glia limitans CNS parenchyma, 
perivascular CNS-associated APCs are ideally situated to present Ag to invading 
myelin-reactive T cells. In the pathogenesis of EAE, during pre-disease onset, DCs 
can be found in the spinal cord white matter and during acute phase and relapse, DCs 
are present in the inflammatory CNS infiltrates (126) (125). These data suggest that 
intracerebral recruitment of DCs plays an important role for the onset and progression 
of the disease. So far it has remained unknown whether the DCs detected in the 
lesions during EAE are BM-derived or stem from DC-precursors located in the 
meninges. Some groups claim that microglial cells resemble myeloid precursors in 
that they display the capacity to differentiate into DCs depending on the cytokine 
environment. It was shown that CD11c+ cells can be generated ex vivo from 
microglial cells upon GM-CSF stimulation (162,163). However, while these DCs in 
the inflamed CNS exhibited a mature phenotype and induced T cell proliferation, no 
in vivo evidence was provided that microglial cells differentiate into DCs. By using 
BM-chimeras with congenic markers, we assessed that CD11c+ cells isolated from the 
CNS were exclusively BM-derived and not of parenchymal origin (microglia).  
Whether CNS-associated DCs participate in Ag-presentation and CNS invasion 
during EAE has so far not been established. Almost 20 years ago, Hickey and Kimura 
demonstrated that blood-borne “perivascular microglial cells” (CNS-associated 
APCs) were competent candidates to present Ag to infiltrating T cells (132). 
Encephalitogenic T cells were adoptively transferred into BM-chimeric rats, in which 
MHCII recognition was restricted to BM-derived cells. They demonstrated that 
hematopoietic derived APCs were necessary and sufficient to confer disease. This 
seminal work was definitely the first claiming that perivascular located APCs could 
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play a major role in mediating CNS-inflammation. It was however not addressed 
whether the encephalitogenic T cells were reactivated in SLTs prior to CNS-invasion. 
The capacity of other hematopoietic-derived cells such as B cells or macrophages to 
function as competent APCs was not excluded in their model. 
Using transgenic mice in which MHCII is exclusively targeted to DCs (all other 
potential APCs including microglia were MHCII-deficient), we showed that DCs 
alone are sufficient to present the cognate Ag to MOG-reactive T cell and are 
permissive for the development of CNS-inflammation. Furthermore, by augmenting 
the number of CNS-associated DCs, upon adoptive transfer with MOG-reactive T 
cells, the disease severity of EAE is increased and the onset of the disease is earlier. 
Detailed analysis of CNS-DCs during EAE revealed that they were predominantly 
myeloid (CD11b+), of a mature phenotype and were exclusively BM-derived. In MS 
lesions, analogous cells, CD209+ DCs, were detected associated with vessels and in 
close proximity to invading T cells. These data indicate that DCs at the interface of 
the immune system and the CNS are the crucial APCs conferring CNS inflammation 
of encephalitogenic T cells.  
Epitope spreading has been well described in inflammatory diseases such as MS, in 
relapsing-remitting EAE and TMEV-IDD (108). It is a process in which reactivity to 
a different epitope than the disease-inducing epitope occurs. In agreement with our 
results, McMahon et al. demonstrated in two mouse models of EAE, that epitope 
spreading occurs directly in the CNS and not in peripheral lymphoid tissues (164). 
They showed that DCs were the most critical APC population associated with the 
CNS to initiate epitope spreading in the inflamed CNS. Neither microglia nor 
macrophages isolated form the CNS were capable of stimulating naive myelin-
specific T cells. Collectively, these in vivo studies strongly suggest that CNS-
associated DCs are able to initiate both primary and secondary T cell responses 
locally. Miller et al. further determined the DC subset in the inflamed CNS that drives 
epitope spreading (165). Myeloid DCs, in comparison to lymphoid DCs, plasmacytoid 
DCs and macrophages, were the most efficient in presenting endogenous peptide as 
assessed by the IL-17 production of CD4+ T cells. Consistent with our results, they 
also observed that these DCs originated in the BM.  
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Taken together, CNS-associated and not CNS resident cells permit the recognition of 
the cognate neuroantigen by CNS invading T cells. However, CNS-resident microglia 
are key players for the maintenance of encephalitogenicity during an immune 
response. 
In MS, neuroantigen-specific T cells, which have escaped tolerance, invade the CNS 
where they initiate a cascade leading to tissue damage. It is definitely established that 
DCs are not only decisive for T cell priming but also T cell tolerance. Several groups 
investigated whether Ags from the CNS could be utilized to induce peripheral 
tolerance and hence prevent the development of the disease. Injections of DCs 
matured with TNF-α and pulsed with MOG were shown to ameliorate the EAE 
disease course (166). Moreover, injection of DCs pulsed with MBP induced tolerance 
and prevented EAE in Lewis rats (167). Interestingly, Suter et al. identified CNS-
localized DCs in the inflamed CNS with regulatory properties (168). DCs that were 
isolated from the CNS of EAE-diseased mice were immature as defined by the 
intermediate and low expression of MHCII and CD80 respectively. These DCs were 
not capable to induce priming of naïve T cells, on the contrary, T cell proliferation 
was inhibited. The presence of such regulatory DCs might contribute to the “immune 
privilege” of the CNS and the limitation of infiltration and disease progression. 
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CONCLUDING REMARKS 
In this thesis, I have discovered that immunization-induced expansion of T 
lymphocytes can occur outside of SLTs. While B cell maturation including the 
production of Abs is highly dependent on the topography of SLTs, T cell immunity 
can develop completely independent of such dedicated lymphoid tissues. The finding 
that SLTs are not a prerequisite for T cell priming has major implications for our 
understanding of the development and evolution of adaptive immune responses and is 
of great interest in the context of vaccination. While intra-nodal immunization has 
been considered as an effective route of vaccination, our findings suggest that this 
concept needs to be revised. As for the development of autoimmune diseases, self-
reactive T cells may not need to be primed in tissue-draining LNs, but could occur at 
the inflammatory site or even in organs distant to the target tissue. Our results point 
towards the liver as an alternative site for successful T cell priming independent of the 
topography of dedicated lymphoid tissues. However, it is feasible that other organs, 
such as the CNS, provide an environment in which auto-aggressive T cells can be 
generated.  
We could demonstrate that when CNS-myelin is the target for such self-reactive T 
lymphocytes, DCs in perivascular spaces are sufficient to present the cognate Ag to 
these T cells in order to mediate CNS-inflammation. After target recognition, self-
reactive T cells migrate through the vessels into the CNS parenchyma where they 
interact with microglia. We have established that microglia are not crucial for T cell 
target recognition but are an absolute requirement for the progression of the 
inflammatory cascade leading to the development of EAE. While the precise factors 
that lead to the collateral tissue damage of myelinating tissue remain to be definitively 
elucidated, our current knowledge on target recognition and the location of vital T 
cell-APC interactions could lead to the development of novel therapeutic strategies 
for the treatment of inflammatory CNS diseases. Under physiological conditions, 
CNS-associated DCs play a role in mediating immune surveillance of the CNS. In 
CNS-mediated autoimmune diseases, a therapeutic strategy could be to target these 
DCs at the interface of the immune system and the CNS in order to reestablish 
peripheral immune tolerance against self and inhibit the progression of T lymphocytes 
into the neuropil.  
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